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Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder characterized by 
degeneration of upper and lower motor neurons in the brain and the spinal cord, respectively. ALS 
is associated with protein misfolding and inclusion formation of several RNA binding proteins, 
such as TAR DNA binding protein (TDP-43) and Fused in Sarcoma (FUS). Matrin3 is a nuclear 
DNA and RNA binding protein and mutations in the gene encoding Matrin3 have been identified 
as a cause of familial ALS (fALS). Matrin3 is an intrinsically disordered RNA binding protein 
with numerous phosphorylation sites. This study attempts to understand the role of the intrinsically 
disordered regions and protein phosphorylation on Matrin3 misfolding and mis-localization using 
a novel yeast model, mammalian neuronal cells, and post-mortem human neuronal tissue from the 
spinal cords of ALS patients. We propose that the intrinsically amino terminal disordered region 
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Summary for lay audience 
 
 
Amyotrophic lateral sclerosis (ALS) is a fatal disease that affects a specific group of nerve cells 
inside our brains and spinal cords called motor neurons. Motor neurons are cells that control the 
movement of our muscles. Scientists have discovered a link between ALS and defects in proteins. 
Proteins are the molecules that carry out most of the functions inside our cells.  For proteins to be 
able to perform their function, they have to attain a specific shape through a well-regulated process 
called protein folding. In ALS, some proteins lose their proper shape and acquire a different one 
which is a process called protein misfolding. These misfolded proteins can accumulate inside the 
neurons, become toxic and prevent the neurons from functioning properly. There are several 
factors that can regulate the process of folding, such as protein phosphorylation and intrinsically 
disordered regions. Protein phosphorylation is the addition of phosphate groups at specific sites in 
the protein to help its proper folding. There is evidence that there are changes in protein 
phosphorylation in ALS patients. Intrinsically disordered regions are parts in some proteins that 
do not have a specific shape due to their high flexibility. This flexibility helps the protein perform 
its function and bind to many other proteins. The downside to this flexibility is that it renders the 
protein prone to misfolding. Scientists have found that many proteins misfolding in ALS have 
intrinsically disordered regions.  
 
In this thesis we explore the misfolding of Matrin3, a nuclear protein that becomes abnormally 
altered in ALS individuals. Matrin3 has many phosphorylation sites and two large intrinsically 
disordered regions, so we decided to study how these factors contribute to Matrin3 misfolding in 
ALS. We began our studies in a yeast model, which allows us to isolate Matrin3 and test its toxicity 
and localization. Interestingly, we discovered that protein phosphorylation and one of the 
intrinsically disordered regions plays a major role in Matrin3 toxicity. Thus, we speculate that 
altered protein phosphorylation and intrinsically disordered regions drive Matrin3 misfolding in 
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1. Chapter 1 
1.1. Neurodegenerative diseases 
 
Neurodegeneration is a broad term encompassing multiple disorders, such as Alzheimer’s disease 
(AD), Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS), and Frontotemporal 
dementia (FTD). These disorders manifest in an age-dependent manner and are characterized by 
progressive loss of neurons. A major hallmark of neurodegenerative disorders is protein misfolding 
and inclusion formation, exemplified by Aβ plaques in AD, Lewy bodies in PD and TDP-43 
aggregates in ALS.1,2 My thesis focuses on describing specific aspects of ALS pathology and 
explores underlying mechanisms.  
 
1.1.1. Amyotrophic lateral sclerosis 
 
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, belongs to a specific 
category of neurodegenerative diseases called motor neuron diseases, which are characterized by 
the loss of upper motor neurons (Betz cells) in the primary motor cortex and lower motor neurons 
in the anterior horn cells of the spinal cord (Figure 1).3,4 The onset of ALS is age-dependent with 
the majority of patients being diagnosed in the sixth decade of life.5 ALS affects approximately 
two in 100,000 individuals with higher prominence  in males compared to females and an increased 
risk for military veterans and athletes.6  
ALS is characterized clinically by progressive muscle weakness, paralysis, and respiratory failure, 
which is the major cause of death in ALS patients.5,6 ALS can be classified based on its heritability 
into sporadic ALS (sALS), which means there is no family history of the disease. sALS represents 
approximately 90% of the ALS cases. Familial ALS (fALS), which means there is a family history 
of the disease, accounts for the remaining 10% of patients.6,7,8 The onset of ALS varies between 
patients; some patients present with limb onset, which means symptoms affect the upper and lower 
limbs first, whereas other patients present with bulbar onset, which means patients first notice 
difficulty in speaking and swallowing. The prognosis of the disease also differs between patients 




type of ALS (sporadic or familial), the mutated gene, and even different mutations in the same 
gene.9 
Currently, there is no effective treatment for ALS. Riluzole and Radicava are the only two FDA 
approved medications for ALS, however studies showed that they can only delay the onset of 
ventilator-dependence and increase the survival of patients by two to three months.10 Similar to 
many other neurodegenerative disorders, such as Alzheimer’s disease and Parkinson’s disease, 
ALS is characterized by a defect in protein processing resulting in protein misfolding, mis-
































A Diagram showing upper motor neurons (UMNs) in the primary motor cortex and lower motor 
neurons (LMNs) in the anterior horn cells of spinal cord. B Diagram showing progressive muscle 
atrophy due to degeneration of motor neurons in ALS.11,12 
A 
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1.1.1.1. ALS-associated protein misfolding 
 
Protein misfolding and mis-localization in the form of protein inclusions in motor neurons is a 
major pathologic hallmark of ALS and many different proteins have been identified to misfold in 
motor neurons of ALS patients. The first gene mutation identified as a cause of fALS affects the 
gene encoding the protein Superoxide dismutase one (SOD1) (Figure 2). SOD1 mutations 
represent 20% of all fALS cases and 1% of all sALS cases.10,13 SOD1 ALS-associated variants 
destabilize native SOD1 and lead to the formation of misfolded aggregates and degradation of 
SOD1.14 Furthermore, SOD1 variants cause the misfolding of wild-type (WT) SOD1, thus 
inducing the aggregation of WT SOD1 and the propagation of SOD1 misfolding in a prion-like 
manner.15,16 
Subsequently, several gene mutations have been identified as a cause of ALS, such as in the gene 
encoding the TAR DNA-binding protein 43 (TDP43), C9orf72, which is the most frequent ALS 
causing gene, Fused in Sarcoma (FUS), and Matrin3 (Figure 2).  All these proteins show 
misfolding and mis-localization not only in fALS patients, but they are also characterised in the 























Diagram showing the timeline of the discovery of several ALS causing genes. The size of the 
circle represents ALS gene frequency. Matrin3 which is the focus of my project in placed in the 

















1.1.1.1.1. TAR DNA binding protein (TDP-43) 
 
Many RNA binding proteins associated with ALS contain prion like domains (PrLDs), including 
FUS, TDP-43, and TAF15. PrLDs plays a critical role in the normal function of these proteins as 
they mediate protein–protein interactions and the formation of stress granules.20,21 Transactive 
response DNA binding protein 43 (TDP-43) is a 414 amino acid, 43 kDa DNA and RNA binding 
protein.22 TDP-43 is a ubiquitously expressed nuclear protein that consists of two RNA recognition 
motifs (RRM1 and RRM2), a nuclear localization signal (NLS), nuclear export signal (NES), and 
a carboxy-terminal PrLD, which mediates multiple protein-protein interactions (Figure 3, A). 22,23 
 
TDP-43 binds DNA and RNA and is involved in RNA regulation and protein synthesis in the cell, 
such as binding, stabilizing, and alternative splicing of mRNA.24 TDP-43 plays a role in other 
cellular processes, such as the transport of RNA granules between the cell body and dendrites of 
neurons and the formation of cytoplasmic stress granules, indicating its role under cellular stress 
conditions, such as oxidative stress.25,26 
 
TDP-43 proteinopathy represented by protein misfolding and inclusion formation of TDP-43 is 
considered a major pathologic hallmark not only in ALS patients, but also in patients suffering 
from other neurodegenerative diseases, such as AD and PD.27 TDP-43 misfolds and forms 
aggregates in 95% of all ALS cases.27 These aggregates are composed of ubiquitinated, 
hyperphosphorylated and truncated fragments of TDP-43 containing the carboxy-terminal of the 
protein (Figure 3, C).7,12,28 Even though protein aggregates are major hallmarks for 
neurodegenerative diseases, their role in the pathogenesis of these disorders is controversial. It has 
long been thought that these aggregates cause neurotoxicity, however, in the recent few years, 
some evidence has emerged indicating that these aggregates are beneficial to neurons by 
sequestering highly toxic oligomers.29 
 
Over 50 mutations in the gene encoding TDP-43 have been identified as a cause of fALS most of 
which are located in the carboxy-terminal PrLD, indicating a possible role of the PrLD on TDP-
43 misfolding (Figure 3, B).30 This has led to extensive studies aimed at understanding the role of 




aggregates, while fragments containing RRM2 and the C-terminal region aggregate with similar 
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A TDP-43 contains two RNA recognition motifs (RRM), a nuclear localization signal (NLS), a 
nuclear export signal (NES) and a carboxy-terminal prion like domain. B The majority of the ALS 
causing mutations in TDP-43 cause amino acid exchanges in the carboxy-terminal PrLD. The 
black lines represent fALS causing amino acid exchanges caused by missense mutations. C TDP-
43 shows nuclear localization in healthy motor neurons. In ALS, TDP-43 mis-localizes and forms 





























1.1.1.1.2. Matrin3  
 
Matrin3 is 125kDa DNA and RNA-binding nuclear matrix protein. Matrin3 is encoded by the 
MATR3 gene which locates on chromosome 5 in humans.33 Matrin3 is one of twelve major inner 
nuclear matrix structural protein that binds to the nuclear lamina.34 It is ubiquitously expressed in 
almost all body tissues with highest expression in the brain.35 The primary structure of Matrin3 
includes: two RNA recognition motifs (RRM1 and RRM2), that recognize and bind RNA. Matrin3 
interacts in an RNA-dependent manner with several proteins with established roles in RNA 
processing e.g., TDP-43 and FUS and maintains its interaction with RNA via its RRM2 domain; 
two Zinc finger domains (ZnF1 and ZnF2), that bind DNA and are also involved in Matrin3 protein 
interactions; a carboxy-terminal nuclear localization signal (NLS); and amino-terminal nuclear 






























Matrin3 contains two RNA recognition motifs (RRM), a carboxy-terminal nuclear localization 






















































Although the exact function that Matrin3 performs in the cells is still unclear, previous studies 
suggest that Matrin3 is involved in different cellular processes, such as binding and stabilizing 
mRNA, nuclear retention of hyper edited RNA, regulation of alternative splicing, regulation of 
chromosomal distribution, and DNA damage repair.39,40,41,42 
Directed studies and unbiased proteome- and transcriptome-wide analyses revealed interactions of 
Matrin3 with different macromolecules, including DNA, RNA and many different proteins. In 
fact, most cellular Matrin3 functions seem to be executed and defined through its interactions with 
other proteins. For example, Matrin3 performs its role in DNA damage response through its 
interaction with NONO/SFPQ. Matrin3 was also found to interact with many well-established 





























Matrin3 interacts with different proteins that help Matrin3 perform its multiple functions. Matrin3 
also interacts with several ALS-associated RNA binding proteins. The thickness of the line 
between the nodes indicates the confidence level of the interaction. This interaction network was 
created using data from the STRING consortium data base. Matrin3 was chosen as the network 






















The first evidence that identified mutations in MATR3 as a cause of fALS was in published by 
Johnson et al. in 2014.44 Upon performing genome sequencing, mutations leading to the amino 
acid substitution Phenylalanine 115 to Cysteine (F115C) in Matrin3 was identified as the cause of 
fALS (Figure 6). After the discovery of MATR3 as an ALS causing genes, further investigations 
were performed on MATR3 identifying additional mutations as a cause of ALS (Figure 6).44 Most 
of the ALS causing mutations are scattered across the entire genes resulting in amino acid changes 
in different regions and are not concentrated in specific domains, as observed for TDP-43 and FUS 
where most ALS-associated mutations localize to their PrLD.30,45  In fact, none of the ALS-causing 
mutations in MATR3 identified so far are located within the RNA binding domains (RRM1 and 










Diagram of the domain structure of Matrin3 including the locations of the ALS causing amino acid 































1.2. Protein folding and misfolding inside the cell 
 
Proteins are complex macromolecules that play essential roles inside our cells, such as maintaining 
cellular structural integrity, intracellular transport, and regulation of gene expression. Therefore, 
maintaining the integrity of the proteome, i.e., the sum of all proteins in a cell or organisms, is 
essential for maintaining viability.46 For proteins to perform their function inside the cells, they 
must attain their distinct native three-dimensional structure. Thus, protein function does not only 
depend on the primary amino acid sequence of the protein, but also on the folding of the protein 
into its distinct, thermodynamically stable conformation.47  
Protein quality control and proper protein folding are facilitated by molecular chaperones. 
Molecular chaperones are a group of proteins, which bind to the nascent peptide during translation 
and fold into its proper three-dimensional structure by providing a favourable environment for 
folding of either the entire protein or a specific region of a protein.48,49,50 
 
Protein misfolding is a process by which proteins do not reach or lose their most stable 
conformation and often displays their hydrophobic amino acid residues on the surface of the 
protein, which is rarely found in properly folded proteins.47 Protein misfolding can occur due to 
stochastic fluctuations, destabilizing mutations, cellular stress conditions, such as a heat shock or 
oxidative stress, or defects in the cellular protein quality control as observed during ageing (Figure 
7).46  
Under normal conditions, cells can prevent the toxic consequences of misfolded proteins through 
multiple pathways facilitated by molecular chaperones and others branches of cellular protein 
quality control, such as protein degradation by the ubiquitin proteasome system (UPS) and 
autophagy.51 Chaperones can bind to misfolded proteins and re-fold them into their proper 
conformation. Chaperones can also target misfolded proteins for degradation by both the UPS and 
autophagy. Finally, if the cellular protein quality control system fails to refold or eliminate 
misfolded protein, they accumulate inside the cell and form inclusions, which are major hallmarks 











Diagram showing proper protein folding and the fate of misfolded proteins. Misfolded proteins 









1.3. Mechanisms of protein misfolding in ALS 
 
1.3.1. Liquid-liquid phase separation 
Liquid-liquid phase separation (LLPS) emerges as a new paradigm underlying the intracellular 
assembly of proteins and other macromolecules, such as RNA. LLPS is a reversible process of a 
homogenous fluid de-mixing into two distinct phases, a condensed phase, and a dilute phase.54,55,56 
LLPS has been identified as a critical physical principle underlying the formation of numerous 
membrane-less cellular organelles, such as p-bodies, stress granules and nucleoli.57,58 In addition 
to membrane-less organelles, other structures are also formed through LLPS, such as transport 
channels in the nuclear pore complex, and membrane receptor clusters at the cell membrane.59,60  
Defects in LLPS have been speculated to drive protein misfolding and aggregation in different 
human diseases, such as cataract and neurodegenerative disorders, including ALS.61,62 For 
example, proteins inside stress granules can undergo liquid-solid phase transition or can nucleate 
to form protein aggregates. This process can be accelerated by disease causing mutations in ALS-
associated genes.  For example, ALS-causing mutations in the gene encoding FUS causes drastic 
changes in the biophysical properties of the liquid droplets and induce rapid formation of protein 
fibrils, which are speculated to be cytotoxic (Figure 8). 63 
A major category of proteins that can undergo LLPS are intrinsically disordered proteins (IDPs). 
Specifically, proteins with intrinsically disordered domains and RNA binding domains, such as 










Figure 8: Aberrant liquid-liquid phase separation (LLPS) can lead to the formation of 







Diagram illustrating LLPS of RNA binding proteins (Blue) and RNA molecules (Red) and the 





















1.3.1.1. Intrinsically disordered proteins 
Proteins with large intrinsically disordered domains (IDDs), commonly known as intrinsically 
disordered proteins (IDPs), represent a large class of macromolecules in the human proteome that 
can undergo LLPS. Intrinsically disordered domains are regions in the protein that lack a defined 
secondary structures and well-structured three-dimensional conformations thus giving them a high 
degree of flexibility.66 Many of the IDD follow a coupled folding and binding process, which 
means that the IDD can fold into stable secondary or even tertiary structures when binding to 
interacting proteins.67  
Unlike predicting the three-dimensional structure of globular protein, which remains a mostly 
unsolved challenge, determining the IDD in a protein is a straightforward process since the amino 
acid composition of the IDD is biased toward low proportions of hydrophobic amino acids and 
high content of polar and charged amino acids.68 Since determining whether a region of a protein 
is disordered or not is a straightforward process, multiple computational algorithms and 
webservers have been developed to detect IDDs such as PONDR, FoldIndex, and DISOPRED. 
69,70,71 IDDs can be further classified according to their amino acid composition such as glutamine-
rich or proline-rich regions.72 
IDPs are abundant in the human proteome, and they play a crucial role in various cellular 
processes, such as regulation of gene transcription, translation, cellular signal transduction, and, 
most importantly, regulation of self-assembly of large multiprotein complexes, such as ribosomes. 
Since IDPs play crucial roles in cells, previous studies have shown that IDD can be highly 











1.3.1.2. Prion-like domains 
 
Prions are infectious proteins that can misfold and adapt a specific, often insoluble conformation, 
which can propagate through healthy cells causing similar or the same kinds of proteins to adopt 
the pathological form.74 Prions cause many devastating neurodegenerative disorders, such as 
Creutzfeldt–Jakob disease, Gerstmann–Sträussler–Scheinker syndrome in humans, and chronic 
wasting disease, scrapie, and mad cow disease in animals. 75,76 
 
Prion-like domains (PrLDs) are a subset of IDDs that are rich in glycine and uncharged amino 
acids. PrLDs were first discovered in yeast and can be identified using hidden Markov algorithms 
in the proteomes of many other organisms.77,78 PrLDs are found in mammalian proteins, especially 
RNA binding proteins, and have similar amino acid composition to that of yeast prions. 77,79   
 
Many RNA binding proteins that have been identified to cause ALS, such as TDP-43 and FUS, 
contain PrLDs.80 PrLDs plays a critical role in the normal function of these proteins; for example, 
the PrLD of TDP-43 mediates protein–protein interactions with splicing factors and facilitate its 
recruitment to stress granules. PrLDs are also crucial for the formation of TDP-43 protein 
aggregates in ALS. The truncation of the c-terminal PrLD eliminated TDP-43 inclusion formation 
and toxicity in different model systems. Furthermore, in ALS, most of the mutations in RNA 
binding proteins occur in the PrLDs, which indicates a major contribution of PrLDs in the 














1.3.1.3. Posttranslational modifications 
 
One of the factors that regulate protein folding and misfolding is posttranslational modification 
(PTMs).  PTMs are a group of chemical alterations of proteins at the later stages of or after protein 
biosynthesis. PTMs range from covalent addition of functional groups to proteolytic cleavages of 
whole protein subunits.82 PTMs, such as phosphorylation, ubiquitination or SUMOylation, can 
alter the conformation and biological function of proteins, can affect protein folding and 
aggregation, and thereby play a role in neurodegenerative diseases.83 For the purpose of my 
project, I focused on protein phosphorylation as major and ubiquitous PTM. 
 
1.3.1.3.1. Protein phosphorylation and protein folding and misfolding 
 
Protein phosphorylation can affect the three-dimensional structure, function, localization, and 
stability of proteins in different ways: it may be required for proper protein folding; it may induce 
conformational changes; it can function as a recognition signal for further modifications, and 
finally, it may modify protein-protein interactions.84 
Changes in the protein phosphorylation pattern are associated with protein misfolding in multiple 
neurodegenerative disorders, including ALS.85 Abnormal phosphorylation takes place in 
deposited, aggregated TDP-43. Multiple phosphorylation sites were identified in the carboxyl-
terminal prion-like domain of aggregated TDP-43. These studies suggest that phosphorylated 
TDP-43 is a major component of pathological inclusions, and that abnormal phosphorylation of 
TDP-43 may be a critical step in the pathogenesis of ALS.27 While it is clear is that phosphorylation 
is relevant in the context of protein misfolding, aggregation, mis-localization and toxicity, the 
mechanism by which protein phosphorylation contribute to the process of protein misfolding and 
then neurodegeneration remains unclear. For example, there is still no evidence suggesting that 
protein phosphorylation is the actual cause rather than merely a consequence of aggregation, or 
whether phosphorylation has a neurotoxic or neuroprotective effect.85 For the purpose of this study, 







1.3.1.3.2.  Matrin3 phosphorylation 
Matrin3 is a phosphoprotein with several phosphorylation sites for tyrosine and serine/threonine 
kinases.  Phosphorylation of tyrosine residues of Matrin3 can modulate its DNA binding activity.86 
Although multiple phosphorylation sites have been identified in Matrin3 only four different protein 
kinases are known to phosphorylate Matrin3. The ataxia-telangiectasia mutated (ATM) kinase 
phosphorylates Matrin3 at serine 208 (Ser208) in response to DNA double stranded breaks (DSBs) 
and thereby activates the DNA damage repair response.42 Previous studies confirmed Matrin3 as 
a novel target of Pyruvate kinase M2 (PKM2)-mediated phosphorylation. PKM2 phosphorylates 
Matrin3’s threonine residue 293 (T239), which inhibits Matrin3 degradation by preventing its 
K48-linked ubiquitylation.87 Matrin3 was also identified as a target for Protein kinase A (PKA)-
mediated phosphorylation. In response to NMDA receptor activation, PKA-mediated Matrin3 
phosphorylation leads to its degradation in the nuclei of neurons in the brain, which leads to 
neuronal death.87 Finally, Mass spectrometry results show that Protein kinase B (PKB) also known 
as Akt, a serine/threonine kinase, also phosphorylates Matrin3.89 
Although many studies have proven that Matrin3 is heavily phosphorylated by many different 
kinases, the contribution of Matrin3 phosphorylation in the pathogenesis of ALS is not yet fully 
understood. There is still no evidence whether there is a change in Matrin3 phosphorylation pattern 
in ALS or not. And if there are any changes, it remains unclear if phosphorylation drives Matrin3 
















1.4. Yeast as a model organism to study protein misfolding  
 
Saccharomyces cerevisiae also known as baker’s yeast or budding yeast is eukaryotic single-celled 
organism that is frequently used to study protein misfolding associated with neurodegenerative 
disorders.90 There are multiple characteristics that qualifies is to be a to be a good model system 
generally:  its unique and vast genetic tools, rapid growth, short cell cycle, the ability to conduct 
high throughput studies, and the availability of genome-wide databases; in fact, yeast was the first 
eukaryotic organism to have its genome fully sequenced and there are deletion and overexpression 
libraries for every yeast gene.91,92 Nearly a third of yeast genes have a direct human orthologues 
and more than two thirds have significant homology with human genes.93 
Yeast cells are also able to adjust their metabolism in response to the provided carbon source in 
the growth media. For example, in media containing fermentable carbon sources, such as glucose 
or galactose, yeast rely on glycolysis and aerobic fermentation as a main source of energy. 
However, in media containing non-fermentable carbon sources, such as glycerol, yeast cells switch 
their metabolism from glycolysis to oxidative phosphorylation carried out by the mitochondria as 
their major source of ATP, which makes yeast cells more similar to many human cells, including 
neurons, which also heavily rely on oxidative phosphorylation for ATP production.94 
The most important characteristic that makes yeast a highly effective model to study protein 
misfolding and its associated toxicity is that most of the cellular pathways involved in cellular 
protein quality, such as molecular chaperones and most proteins involved in protein degradation 
are highly conserved between humans and yeast.95,96 
 
In sum, yeast is a very powerful tool to study protein misfolding of protein involved in 
neurodegenerative diseases. There are several established yeast models to study protein misfolding 
in various neurodegenerative disorders, such as α-synuclein (α-syn) and parkin (PARK2) yeast 
models for Parkinson’s Disease (PD), the Huntington (Htt) polyQ expansion in Huntington’s 
Disease (HD), and TDP-43 and FUS in ALS. Of note, many studies using yeast models have 
produced results that deciphered genetic and cellular mechanisms underlying protein misfolding 
that are highly relevant to human neurodegeneration.97 For the purpose of this study, we 





1.5. Mammalian neuronal cell model: SN56 cells 
 
The next step after establishing our yeast model is to evaluate the translational nature of our yeast 
results in mammalian neuronal cells. In this study we used SN56 cell line, which is a mouse 
cholinergic septal neuronal cell line that is frequently used to study different neurodegenerative 
disorders. For instance, SN56 cells have been used to study the misfolding of several ALS-




1.6.1. Matrin3 phosphorylation 
 
Protein phosphorylation can affect the three-dimensional structure, function, and fate of proteins 
in many different ways. Protein phosphorylation may induce conformational changes that can lead 
to protein misfolding and inclusion formation.84 Many studies have explored protein 
phosphorylation in the context of neurodegeneration, for example, abnormal phosphorylation 
pattern has been observed in TDP-43 inclusions in ALS patients. These studies suggest that 
abnormal phosphorylation of TDP-43 is a critical step in the pathogenesis of ALS and FTD.27 
Matrin3 is heavily phosphorylated, but the contribution of Matrin3 phosphorylation to the 
pathogenesis of ALS is not yet fully understood. There is still no evidence whether there is a 
change in Matrin3 phosphorylation pattern in ALS or not. And if there are any changes, do 
these drive Matrin3 misfolding and mis-localization or are they just a consequence of protein 












1.6.2. Intrinsically disordered domain and Matrin3 misfolding 
 
LLPS is reversible process of a homogenous fluid de-mixing into two distinct phases, a 
condensed phase, and a dilute phase.54,55 There is increasing evidence that defects in phase 
separation process might be the driving force for protein misfolding and aggregation in 
neurodegenerative diseases including ALS.61,62 Proteins contain large intrinsically disordered 
regions such as prion like domains can undergo LLPS. Many of the RNA binding proteins, such 
as TDP-43 and FUS that are associated with ALS, contain prion-like domains and most of the 
fALS causing amino acid changes in these proteins occur in prion-like domains.64,80 This 
indicates that intrinsically disordered regions play a role in the process of protein misfolding 
and aggregate formation. Previous studies have shown that Matrin3 is an intrinsically 
disordered protein, and the amino terminal regions is required for Matrin3 to undergo 
LLPS.18,100 In this study, we seek to determine the role of the intrinsically disordered regions 
on Matrin3 misfolding and toxicity. 
 
1.7. Hypothesis, Objectives  
 
We hypothesize that Matrin3 phosphorylation and its intrinsically disordered domains drive 
Matrin3 aggregation and toxicity in yeast and neuronal cells models of ALS. 
 
My specific objectives are: 
1. Detect Matrin3 aggregation and mis-localization in patients with sporadic and 
familial ALS.  
2. Determine the effect of Matrin3 phosphorylation on its toxicity and localization in 
the yeast model and in cultured mammalian neuronal cells. 
3. Determine the role of the amino-terminal disordered domain, its toxicity, and 









In order to fully understand the pathological mechanisms underlying protein misfolding in ALS, 
we must focus on fundamental mechanistic aspects, using experimentally tractable model 
organisms, such as yeast and cultured neuronal cells before we can start meaningful experiments 
in animal models. Protein aggregation is the hallmark of many neurodegenerative diseases. 1,2 
Studying the mechanisms underlying Martin3 misfolding will provide insight on the role of PTMs 
and IDD on protein misfolding and toxicity in ALS and eventually develop a therapeutic solution 














2 Materials and methods 
2.1. Materials 
2.1.1. Yeast strains  
Yeast W303 (MAT a leu2- 3,112 trp1-1 can1-100 ura3-1 ade2-1 his3-11,15) and W303 Dpdr5 
(MAT a leu2- 3,112 trp1-1 can1-100 ura3-1 ade2-1 his3-11,15, Dpdr5) strains were used in this 
study. 
2.1.2.  E. coli strains  
Escherichia coli Strain DH5α Genotype F–Φ80lacZΔM15 Δ(lacZYA-argF) 169 recA1 endA1 
hsdR17 (rK–, mK+) phoA supE44 λ– thi-1 gyrA96 relA1 was used in this study. Subcloning 
efficient DH5α Competent Cells (Invitrogen, Cat. No. 18265-017) were used for the cloning work 
in this study.  
2.1.3.  Mammalian cell lines 
SN56 cell line; a mouse cholinergic septal neuronal cell line was used in this study. The SN56 
cells were provided by Dr. Marco Prado (Robarts Research Institute, University of Western 
Ontario). 
 
Table 1: Yeast growth media  
 




10 g/L yeast extract, 20 g/L 
peptone, 20 g/L glucose 
 
Rich yeast media used for non-
selective yeast growth in liquid media 



















2% glucose, Yeast Nitrogen 
Base (YNB), 6 g/L L-isoleucine, 
2 g/L L-arginine, 4 g/L L-lysine, 
6 g/L L-phenylalanine, 1 g/L L-
threonine 
 
Selective amino acids: 
4g/L L-tryptophan, 6 g/L L-
leucine, 2 g/L L-histidine, 2g/L 




Synthetic yeast media. Used for either 
non-selective yeast growth (when all 
selective amino acids are present) or 
for selective growth, when one of 
them is absent. 











2% galactose, Yeast Nitrogen 
Base (YNB), 6 g/L L-isoleucine, 
2 g/L L-arginine, 4 g/L L-lysine, 
6 g/L L-phenylalanine, 1 g/L L-
threonine, 1 g/L L-methionine 
 
Selective amino acids: 
4g/L L-tryptophan, 6 g/L L-




Synthetic yeast media. Used for 
protein expression induction 
Can be used as liquid media or for agar 
plates* 
*23 g/L agar was used for preparing agar plates 
 
Table 2: E. coli growth media  
 
Name Composition Description 
 
Lysogeny (LB) broth 
 
 
5 g NaCl 
5 g yeast extract 






Media for selective e. coli 
growth, transformations, and 
cloning 
 
Can be used as liquid media or 
for agar plates* 
 




2x Yeast extract Tryptone 5 g NaCl 
10 g yeast extract 
16 g tryptone 
 
Rich yeast media used for e. 
coli recovery after 
transformation 




Table 3: Mammalian cell growth media  
 
Name Composition Description 
Dulbecco's Modified Eagle 
Medium (DMEM, Wisnet) 
10% fetal bovine serum 
1x penicillin/streptomycin 
Basal media for mammalian 
cell growth 




2.1.4.  DNA Plasmids  
















Expression of MATR3 WT, 
missense mutations, and 
truncated variants in yeast  
 
Susan Lindquist. Addgene number: 







Expression of MATR3 WT 
in yeast  
 
Susan Lindquist. Addgene number: 







Expression of MATR3 WT, 
missense mutations and 
 











PAAV CMR IRES GFP 
ccdB Stop/HA 
 
Expression of MATR3 WT, 
missense mutations, and 






2.1.5.  Antibodies 
Table 5: Antibodies 





























































2.1.6.  Additional Key Reagents 
Table 6: Additional key reagents and chemicals  











Oxidizing agent. Induces 
protein, lipid, and nucleic 
acid damage. Induces 








Highly sensitive method for 
detecting proteins bound to 




Gateway Cloning Kit 
 








Production of MART3 
mutation variants 
 
New England BioLabs (NEB) 
 
QIAprep Spin Miniprep Kit 
 
 




QIAQuick gel extraction kit Agarose gel DNA extraction Qiagen 
 
PierceTM BCA Protein 
Assay Kit 
 




Lipofectamine LTX Mammalian cell transfection ThermoFisher Scientific  
 
CellTiter-Glo Luminescent 
Cell Viability Assay 
 
Method for determining the 











Table 7: Human spinal cord tissue samples   
Human spinal cord tissues samples (controls and ALS cases) were kindly provided by the 
team of Dr. Michael Strong (Robarts Research Institute, University of Western Ontario). 
  
Case Number Tissue Type Source 
09-006 A7 SC control Strong Lab 
97-139 N8  SC control Strong Lab 
97-148 N6 SC control Strong Lab 
97-033 N5 SC control Strong Lab 
97-070 N11 SC control Strong Lab 
A01-25 14 SC sALS Strong Lab 
A01-115 N7 SC sALS Strong Lab 
A01-342 N30 SC sALS Strong Lab 
A01-363 N3 SC sALS Strong Lab 
87702 N37/33 SC sALS Strong Lab 
94165 N10 SC sALS Strong Lab 
95205 N2 SC sALS Strong Lab 
98027 N17 SC sALS Strong Lab 
98112 N10 SC sALS Strong Lab 
00417 N8 SC sALS Strong Lab 
00410 N7 SC sALS Strong Lab 
98-052 N12 SC SOD1 (113T) Strong Lab 
04-511 A24 SC SOD1 (D76Y) Strong Lab 




01-444 N12 SC C9orf72 Strong Lab 
05-407 A20 SC C9orf72 Strong Lab 
01-164 N26 SC C9orf72 Strong Lab 
01-217 N9 SC C9orf72 Strong Lab 
97187 N13 SC C9orf72 Strong Lab 
93159 17 SC C9orf72 Strong Lab 
09096 A28 SC C9orf72 Strong Lab 
06266 A22 SC C9orf72 Strong Lab 
00056 N7 SC C9orf72 Strong Lab 
 
2.2. Experimental methods 
2.2.1. Matrin3 in silico analysis 
A Charge hydropathy plot was produced using PONDR according to the method introduced by 
Uversky et al. The plotting was performed using MATLAB software. Four webservers MFDp2, 
PONDR, IUPred2A, and DISOPRED3 were used to predict the intrinsically disordered regions in 
the protein. Matrin3 post translational modification: PhosphoSitePlus data was used for the 
Matrin3. Low- and high-throughput numbers were summed for each site. Plotting was performed 
in MATLAB. 
2.2.2. Cloning of MATR3 and creation of MATR3 mutant variants 
2.2.2.1. Gateway cloning 
2.2.2.1.1. BP reaction 
The BP recombination reaction was performed by combining 2μl of destination vector plasmid 
DNA (about 100- 200 ng of DNA) or PCR product, 1 μl of pDONR vector (150 ng/μl), and 2 μl 
of 5X BP Clonase (Invitrogen). The mixture is vortexed and centrifuged twice to ensure thorough 
mixing and then allowed to incubate overnight at 30°C. 1 μl of Proteinase K (Invitrogen) solution 




reaction mixture is then used to transform into Subcloning Efficiency DH5α Competent Cells 
(Invitrogen, Cat. No. 18265-017) following the protocol provided by the manufacturer. The cells 
are plated in LB kanamycin (kan) resistant agar plates and incubated overnight at 37°C. Colonies 
are picked from the plates and inoculated into LB kan liquid overnight at 37°C. The plasmids are 
then extracted from the E. coli cells by using the High-Speed Plasmid Mini Kit (Qiagen); the 
resulting DNA is in pDONR vector backbone.  
2.2.2.1.2. LR reaction  
The LR recombination reaction uses 1μl of the product (100-300 ng) from the BP reaction, i.e., 
the pDONR vector, in combination with 2μl of destination vector (150 ng/μl), 13μl of TE buffer, 
and 4μl of LR Clonase (Invitrogen). The destination vectors used are listed in section 2.1.4. The 
mixture is vortexed and centrifuged twice and allowed to incubate overnight at 37°C. The resulting 
procedure is the same as described for the BP recombination reaction—Proteinase K is added to 
the mixture, incubated, and transformed into competent cells. The destination vectors are 
ampicillin (amp) resistant and therefore must be plated on LB amp agar plates and then inoculated 
in LB amp liquid media.  
2.2.2.2. Cloning of WT MATR3  
 
MATR3 was PCR-amplified from human WT MATR3 template provided by Dr. Jeehye Park 
(Hospital of sick kids, Toronto, ON, 416-813-7670). 
The PCR product was cloned into pDONR201 vector (Table 5) using Gateway® technology 
(Invitrogen) BP reaction and following the manufacturer’s protocols. The correct sequence of the 
entry clones was confirmed by Sanger sequencing (performed by Robarts London Regional 
Genomics Centre). MATR3 was cloned into p423GAL-Stop/YFP, p413 GPD-Stop/YFP and p413 
Met-Stop (Table 5) plasmids using the LR reaction. The identity of the destination vector 





2.2.2.3. Cloning of MATR3 mutants 
Wild type pDONR201 MATR3 template (10-25 ng) was PCR amplified with Q5 Hot Start High-
Fidelity kit (Table 5) and non-overlapping mutagenetic primers in a 25ul reaction. The resulting 
PCR products were ligated using the Kinase, Ligase, and Dpn1 (KLD) reaction and transformed 
into E. coli. Several colonies were then picked and inoculated in 3mL of liquid LB Kan overnight. 
Cultures were then centrifuged, and DNA was extracted from the pellets using the QIAprep Spin 
Miniprep kit (Table 5). The presence of mutations was then verified by Sanger sequencing 
(performed by Robarts London Regional Genomics Centre). Mutated DNA was then cloned into 
pAG423 Gal-Stop/YFP, pAG413 GPD Stop/YFP destination vector (Table 5) using the LR 
reaction. The identity of the destination vector containing the mutated DNA was verified using 
restriction digest.  
2.2.2.4. Cloning of MATR3 truncated fragments 
Wild type pDONR201 MATR3 template (10-25 ng) was PCR amplified with Q5 High-Fidelity kit 
(Table 5) and non-overlapping truncation primers in a 25µl reaction The PCR product was cloned 
into pDONR201 vector (Table 5) using Gateway® technology (Invitrogen) BP reaction and 
following the manufacturer’s protocols. The correct sequence of the entry clones was confirmed 
by Sanger sequencing (performed by Robarts London Regional Genomics Centre). MATR3 was 
cloned into p423GAL-Stop/YFP, and p413 Met-Stop (Table 5) plasmids using the LR reaction. 
The identity of the destination vector containing MATR3 was verified by restriction digest. 
2.2.2.5. Gel purification 
 
PCR products were confirmed by running the DNA on 1% agarose gel. The PCR products were 







2.2.2.6. DNA Isolation 
 
After DNA cloning and E. coli transformation, DNA was isolated using Qiagen Miniprep Kit 
according to table 6. 
 
2.2.3. E. coli transformation 
We performed E. coli transformations to replicate and amplify plasmid DNA, resulting in abundant 
amounts of DNA. 100 μl aliquots of transformation competent DH5α cells were thawed on ice 
from storage at -80° C; 1-5 μL (0.1~0.5 μg) of plasmid DNA was added to the cells and mixed 
thorough by gently flicking the tubes (the competent cells should not be vortexed). The cells were 
allowed to recover on ice for about 30 mins and heat shocked at 40°C for 45 seconds. The cells 
rested on ice for 2 mins before 1 mL of 2xYT was added and the cells allowed to recover at 37° C 
in a shaking incubator for at least 1 hour. Following recovery, the cells were centrifuged at 10,000 
xg for one minute, the supernatant was aspirated off, and the pellet was resuspended in 100 μl of 
2xYT. The suspension was plated on LB agar plates with selective antibiotic depending on the 
antibiotic resistance of the vector.  
2.2.4. Yeast transformation 
 
DNA constructs containing the human MATR3 were transformed into yeast cells by the lithium 
acetate methods to produce yeast strains that stably express Matrin3 when kept under selective 
auxotrophic selection in their growth media. In brief, single colonies of yeast cells were 
inoculated into 3 mL of liquid media and incubated at 30° C with shaking overnight. The liquid 
culture was then diluted to a 30 mL liquid culture with medium and incubated at 30° C shaking 
till the cells reached mid logarithmic growth phase (an OD600 of 0.4 to 0.5). The culture was 
then centrifuged for 5 minutes to pellet the yeast cells. The supernatant was aspirated off, 
discarded and the pellet was washed with 3 ml of sterile water. The cells were centrifuged again 
at the same speed and time. The pellet was resuspended in 2 ml of 100 mM Li-Acetate in TE 
buffer after the wash step and incubated at 30°C shaking for 10 minutes. The culture was 




transformation. Each transformation was composed of 100 μl cell suspension, 250 μl 
transformation (1 X TE, 40% PEG, and 100mM Li-Acetate), 12μl salmon sperm DNA, 1μl 
(0.3~0.5 μg) plasmid DNA, and 25μl DMSO and in the order listed and vortexed thoroughly. 
The cells then recovered at 30° C shaking for 30 minutes, following a 20-minute of heat shock 
at 42° C shaking. After heat shock, the cells were centrifuged for 1 minute at 2000 xg, the 
supernatant was aspirated, and the pellet resuspended in 50 μl TE buffer. The cells were then 
plated onto selective agar plates. 
 
2.2.5. Yeast spotting assay 
 
Yeast growth (spotting) assays were carried out by inoculating yeast strains overnight in 3ml of 
selective growth media at 30°C and grown to saturation. The optical density (OD600) was 
measured for each strain following 16 hours of growth by diluting 100µl of yeast into 900µl of 
water. Diluted cultures were vortexed and added to a cuvette and the OD600 is measured by a 
spectrophotometer. To ensure equal number of cells are plated in the assay, cultures were 
normalized to a standard .02 OD600 across conditions. Normalized cultures were transferred to 
the top wells of sterile 96-well plates (Greiner bio-one #650161). A five-fold serial dilution was 
performed using a multichannel pipette to transfer 30µl of the normalized cultures into 120µl 
of water. Cell dilutions were then transferred to agar plates using a sterilized, 48-pin “replicate 
- plater”. Cells were spotted on non-inducing, overgrowth controls and inducing, selective plate. 
2.2.5.1. Spotting assay quantification 
 
The growth of yeast cells was then quantified using mean gray value densitometry in ImageJ 
software as described before.101 The mean gray values of a single spot and of the plate background 
(no yeast colonies present) were measured on a grayscale, 8-bit image of a spotting assay. The 
mean gray value of the background was subtracted from the mean gray value of the spot. Those 
values were divided by the mean gray value of the positive control, yielding a value that represents 
the relative amount of yeast cell growth for that dilution.  Relative mean growth values from three 
independent biological replicates were statistically analyzed to identify any significant differences 




results consisted of a one-way ANOVA followed by a post-hoc Tukey’s HSD test (95% confidence 
level) and was performed using the RStudio software. 
 
 
2.2.6. Live cell fluorescence microscopy 
 
Microscopy imaging of YFP tagged constructs was done by first inoculating yeast cells in SD 
media at 30°C overnight. The cells are then washed twice with ddH2O, resuspended in SD media, 
or various stress condition media (AZC, H2O2, and Radicicol) incubated at 30°C (37°C to induce 
heat stress). After inducing for 16 to 20 hours, 2µl of the liquid culture are placed on a microscope 
slide. Fluorescence microscopy was performed using the Cytation5 cell imaging multi-mode 
reader (BioTek, Winooski, WI, USA). LED cubes and imaging filter cubes from biotech were 
employed for YFP tagged proteins: 465 LED 1225001 Rev J, GFP 469/525 1225101 Rev J, 
BioTekImages were captured on the 20× objective. Image analysis was completed using the Gen5 
imaging software (BioTek) 
 
2.2.7. Western blot 
2.2.7.1. Alkaline lysis of yeast cells 
For preparing total protein lysates in yeast, liquid yeast cultures were grown overnight and 
centrifuged. The pellet was resuspended in 100µl ddH2O and 100µl of 0.2 M NaOH and incubated 
at room temperature for 10 minutes. The sample was then centrifuged, and the pellet was 
resuspended in 50µl of SDS sample buffer (0.06 M Tris-HCl pH 6.8, 5% Glycerol, 2% SDS, 4% 
BME, 0.0025% BromoPhenol Blue) and boiled for 3 minutes. The sample is then centrifuged for 
a final time. The supernatant was obtained and loaded into the gel.104 
2.2.7.2. Mammalian cell lysis  
For preparing total protein lysates in mammalian cells, Cells were washed with cold PBS which 




cold lysis buffer (50 mM Hepes pH 7.5, 150 mM NaCl, 5 mM EDTA, 1% (v/v) Triton X-100, and 
SIGMA FASTTM Protease Inhibitor), after which cell lysates were frozen at -20°C. After thawing 
on ice, lysates were subjected to a Branson Sonifier® ultrasonic cell disruptor for two 3-5 sec 
pulses. Lysates were then centrifuged at 20000×g for 10 min at 4°C. The supernatants were 
obtained, and protein concentrations were determined using the BCA kit. The samples were then 
loaded into the gel at the appropriate concentrations.  
2.2.7.3. Normalization of protein concentrations (mammalian cells) 
We perform a BCA Protein Assay to determine the concentration of protein in the sample. The 
assay was performed according to the Thermo Scientific Pierce BCA Protein Assay Kit 
Instructions. After obtaining the concentration and normalizing the total protein amount in each 
sample per blot, we dilute the samples with 4x reducing SDS buffer (0.25M Trisma Base pH 6.8, 
8.0% SDS, 40% sterile glycerol, 10% β-mercaptoethanol, 0.04% bromophenol blue).  
2.2.7.4. SDS-PAGE 
We run SDS-PAGE with the samples on an 8-16% gradient gel (Bio-Rad Criterion TGX Stain-
Free Precast Gels) or 12% acrylamide gels at 220 V for about 30 mins. The gel is then transferred 
onto a Nitrocellulose or PVDF membranes (BioRad) using the Bio- Rad Trans-Blot Turbo machine 
following the manufacturer’s protocol. We then block the membrane using 5 or 10% skim milk 
powder (Carnation) in Phosphate Buffered Saline with 0.01 % (v/v) Tween (PBST) and incubating 
for 1 hour on a shaker. The membrane is then incubated in primary antibody overnight on shaker. 
Following incubation with the primary antibody, we wash the membrane with 50mL aliquots of 
PBST at ten-minute intervals for an hour on shaker and then incubate in the secondary antibody 
for 1 hour on a shaker. The membrane is washed again with 50mL aliquots of PBST in ten minutes 
intervals on shaker for an hour. The membrane is then documented using the ChemiDoc MP 
System (Bio-Rad).  
2.2.8. Mammalian cell viability assay 
The CellTiter-Glo Luminescent Cell Viability Assay (Promega) was used in this study. This assay 




toxicity associated with misfolded proteins. Transfected SN56 cells are split into 96 well plates 
and grown in minimum DMEM with 1% fetal bovine serum (FBS, Gibco) and 1 g/L glucose. This 
minimal medium increase sensitivity to the toxic effects of protein misfolding in many other 
systems, as well as differentiating N2a cells. The cells are incubated at 37 °C for 20~24 hr. The 
cell viability assay is then performed according to the supplier’s instructions. Plates were then 
measured using the Cytation 5 Cell Imaging Multi-Mode Reader (Biotek).  
2.2.9. Immunofluorescence microscopy 
 
Following transfection, the cells are split into 8 well chambers (Labtek) and grown in DMEM at 
37°C for 20~24 hr. Each well is seeded with ca. 30,000 cells. The media is then aspirated off and 
the cells washed 2 times with PBS. 4% paraformaldehyde is then added to the wells to fix the cells 
for 15 min. This is followed by 3 washes in PBS. The cells are permeablized with 0.5% TritonX-
100 in PBS for 15 mins and washed with PBS 3 times, followed by 5 washes in 0.5% BSA (Sigma) 
in PBS (PBB). We block non- specific binding sites with 20% normal goat serum (Gibco) in PBB 
for 45 min. The cells are then washed with PBB 5 times and incubated for an hour in rabbit anti-
Matrin3 polyclonal antibody (Thermofischer MATR3 antibody 1:1000 dilution). We wash the 
cells with PBB 5 times and incubate for an hour in α-rabbit Texas red secondary antibody (Thermo 
Fisher). Following the secondary antibody incubation, we wash in PBB 5 times. All the liquid is 
then aspirated off and mounted with ProLong® Gold Antifade Mountant with DAPI. SN56 cells 




Immunohistochemistry was used to stain for Matrin3 in human brain and spinal cord. Slides 
were de-paraffinized in xylene and rehydrated in 100% ethanol, 95% ethanol, 70% ethanol, 
ddH2O and quench (20 mL 30% H2O2 and 180 mL methanol) to prepare them for staining. 
Antigen retrieval was conducted in a pH 6 citrate buffer in a decloaking pressure chamber. 
Slides were blocked for 30 minutes using 2.5% horse serum. They were then incubated 
overnight in primary antibody solutions at 4°C. Rabbit anti-Matrin3 polyclonal antibody (Sigma 




primary antibody. Slides were then incubated with the ImmPress kit horse-radish peroxidase 
micro-polymer solution and DNAJC7 was visualized using Diaminobenzidine (DAB) solution 
incubation for 10 mins. Slides were stained with hematoxylin, washed and then mounted and 
covered. 
 
2.2.11. Statistical analysis: 
 
Statistical analysis of the viability assays, western blots, and aggregation quantifications were 
completed using the GraphPad Prism 6 software. Statistical significance was obtained by 
performing unpaired t-tests to compare the means and standard deviations between the control data 
set and the experiment data set (each at a minimum of three biological replicas). Significance levels 

































3.1. Matrin3 localization in motor neurons of the ventral horn in the spinal cords of 
of sALS, fALS patients, and neurologically unaffected controls 
The aim of my first set of experiments is to determine Matrin3 localization in ALS patients in 
motor neurons of the spinal cord, which are the neurons most affected by neurodegeneration in 
ALS.3,4 To this end, I performed immunohistochemical analysis on paraffin-embedded formalin-
fixed spinal cord tissue of unaffected controls (n=5), sALS patients (n=11) and fALS patients 
carrying mutations in Super oxide dismutase 1 (SOD1) (n=3) or C9orf72 (n=9). My analyses 
focused on motor neurons located in the anterior horn of the spinal cord. Motor neurons were 
identified by their characteristic large size compared to other neurons and glia cells and their 
overall unique morphology.44 
Immunohistochemical staining of unaffected controls showed weak granular nuclear staining of 
Matrin3 without any cytosolic staining, which can indicate Matrin3 binding to the chromatin or 
highly expressed RNA molecules.44 Immunohistochemical staining of sALS patient tissue showed 
intense nuclear staining with occasional nuclear inclusions and diffuse cytosolic staining indicating 
Matrin3 mis-localization comparable to TDP-43 in ALS. Immunohistochemical Matrin3 staining 
of fALS tissues with SOD1 mutations showed variable Matrin3 staining depending on the SOD1 
mutation: A4T and I113T mutations did not affect Matrin3 localization compared to unaffected 
controls. By contrast, in a case with a SOD1 D76Y mutation, Matrin3 showed nuclear staining 
with intense diffuse cytosolic staining. Finally, immunohistochemical staining of fALS with 












Figure 9: Localization of Matrin3 in the anterior horn of the human spinal cord of unaffected 


































































In silico analyses predict Matrin3 as a disordered protein. A Charge-hydropathy plot predicts Matrin3 as a disordered protein. The plot is produced using PONDR webserver. A linear 
boundary can mostly separate the ordered (blue) and disorder proteins (red). Matrin-3 and FUS/TLS both fall on the disordered side of the plot, while TDP-43 falls on the ordered side. 
Plotting was performed in MATLAB.  Four webservers MFDp2, PONDR-Fit, IUPred2A, and DISOPRED3 were chosen were used tp predict the disordered domains for: B TDP-43 and C 
Matrin3. A con!dence value below 0.5 indicates a residue is likely to belong to an ordered region, while a value above 0.5 indicates a residue is likely to belong to a disordered region. 
Motifs/domains are drawn and placed approximately to scale. Lower values indicate the boundaries while upper values indicate the con!dence of the assignment. Areas with motif 
or domain assignment show increased order as well as a 50 residue stretch in the N-terminal region (100-150). Plotting was performed in Graphpad Prism.
Matrin-3 post-translational modi!cations. PhosphoSitePlus data was plotted for the human Matrin-3 entry. Low- and 
high-throughput numbers were summed for each site. The magnitude of the phosphorylation at residue S188 (denoted 
with an asterisk) was halved (the total number of references at this site is 388). A high degree of postranslational modi!ca-






















Type Granular Nuclear Intense Nuclear 
(Inclusions) 
Diffuse Cytosolic 
Controls (5) 5 0 0 
sALS (11) 2 9 5 
C9orf72 (9) 1 8 0 
SOD1 
 
A4T (1) 1 0 0 
D76Y (1) 0 1 1 
I113T (1) 1 0 0 
 
 
A Schematic presentation of the anterior horn of the human spinal cord. B Immunohistochemistry 
images of the anterior horn of the human spinal cord from unaffected individuals (control). C 
Immunohistochemistry images of the anterior horn of the human spinal cord from sALS patients. 
D Immunohistochemistry images of the anterior horn of the human spinal cord from fALS patients 
with three different SOD1 mutations. E Immunohistochemistry images of the anterior horn of the 


















3.2. In-Silico analysis of Matrin3 
After confirming that Matrin3 can misfold and form inclusions and shows aberrant localization 
patterns in many ALS cases, we investigated the mechanism underlying Matrin3 misfolding. To 
address this aim, we explored three aspects that can regulate Matrin3 folding and misfolding: ALS 




3.2.1. ALS-associated variants of Matrin3 
 
We used several databases (ClinVar, Project MinE and ALSKP) to determine the sites of fALS 
associated mutations. We found a total of 35 different missense mutations in the MATR3 gene in 































Table 8: All identified ALS causing mutations in MATR3  
 Mutation 
1 S 61 N 
2 Q 66 K 
3 A 72 T 
4 S 85 C 
5 S 99 C 
6 R 102 H 
7 F 115 C 
8 D 131 E 
9 G 153 C 
10 P 154 S 
11 D 187 E 
12 R 317 C 
13 N 333 S 
14  P 368 T 
15 G 377 D 
16 M 389 V 
17 Q 390 H 
18 G 392 V 
19 V 394 M 
20 R 595 G 
21 S 596 T 










































23 T 622 A 
24 E 623 K 
25 Q 627 E 
26 D 641 H 
27 E 664 A 
28 A 688 S 
29 S 707 L 
30 K 712 D 
31 N 740 S 
32 A 751 T 
33 S 759 G 
34 N787 S 
35 V 790 F 
 
A Diagram of fALS-associated variants of Matrin3 caused by missense mutations in the MATR3 
gene. Three different databases (ClinVar, Project MinE and ALSKP) were employed to identify 
these mutations. B List of all ALS-associated amino acid changes caused by missense mutations 
in Matrin3 and their amino acid positions. The colours represent the predicted severity of the 



















3.2.2. Posttranslational modification sites of Matrin3 
 
Since post-translational modifications can play an important role in protein folding and often 
characterizes pathological inclusions in neurodegenerative disease 27,83, I used Phosphosite plus 
webserver to determine the post-translational modifications of Matrin3. This analysis indicated 
that Matrin3 contains many serine/threonine and tyrosine phosphorylation sites. Matrin3 also 
contains several ubiquitination, methylation, and acetylation sites (Figure 11). The results show 
that most of the post translational modifications occur in the disordered regions of Matrin3 (Figure 






























A Diagram of Matrin3 PhosphoSitePlus data was plotted for the human Matrin3 entry. Low- and 
high-throughput numbers were summed for each site. The magnitude of the phosphorylation at 
residue S188 (denoted with an asterisk) was halved (the total number of references at this site is 
388) to fit it within the graph. A high degree of postranslational modifications is present in the 










































Matrin-3 post-translational modi!cations. PhosphoSitePlus data was plotted for the human Matrin-3 entry. Low- and 
high-throughput numbers were summed for each site. The magnitude of the phosphorylation at residue S188 (denoted 
with an asterisk) was halved (the total number of references at this site is 388). A high degree of postranslational modi!ca-






3.2.3. Intrinsically disordered domains of Matrin3 
 
After using several databases to determine the fALS-causing mutations in Matrin3, we found that 
the mutations were scattered over the whole length of the protein, unlike the majority of the ALS 
associated RNA binding protein, such as TDP-43 and FUS, which contain most of their mutations 
in the intrinsically disordered PrLD. 81 Since there is no evidence in the literature that Matrin3 
contains a PrLD, we decided to perform computational analyses to determine if Matrin3 contains 
intrinsically disordered domains, which can contribute to protein misfolding. First, we generated 
a charge hydropathy plot using PONDR webserver, which predicted Matrin3 to be a disordered 
protein. The inclined black line represents the boundary line between ordered proteins (blue) and 
disordered protein (red). (Figure 12, A). Secondly, we used four different webservers (MFDp2, 
PONDR-Fit, IUPred2A, and DISOPRED3) to determine which domains of Matrin3 are 
disordered. We also conducted an analysis of TDP-43 as a control and reference. TDP-43 analysis 
shows that all the protein is highly ordered except for the carboxy-terminal PrLD (Figure 12, B).  
Our analysis also showed that Matrin3 protein is almost completely disordered except for the 



















Figure 12: In silico analyses predicts Matrin3 to contain intrinsically disordered domains. 
 
                    





































































In silico analyses predict Matrin3 as a disordered protein. A Charge-hydropathy plot predicts Matrin3 as a disordered protein. The plot is produced using PONDR webserver. A linear 
boundary can mostly separate the ordered (blue) and disorder proteins (red). Matrin-3 and FUS/TLS both fall on the disordered side of the plot, while TDP-43 falls on the ordered side. 
Plotting was performed in MATLAB.  Four webservers MFDp2, PONDR-Fit, IUPred2A, and DISOPRED3 were chosen were used tp predict the disordered domains for: B TDP-43 and C 
Matrin3. A con!dence value below 0.5 indicates a residue is likely to belong to an ordered region, while a value above 0.5 indicates a residue is likely to belong to a disordered region. 
Motifs/domains are drawn and placed approximately to scale. Lower values indicate the boundaries while upper values indicate the con!dence of the assignment. Areas with motif 
or domain assignment show increased order as well as a 50 residue stretch in the N-terminal region (100-150). Plotting was performed in Graphpad Prism.
Matrin-3 post-translational modi!cations. PhosphoSitePlus data was plotted for the human Matrin-3 entry. Low- and 
high-throughput numbers were summed for each site. The magnitude of the phosphorylation at residue S188 (denoted 
with an asterisk) was halved (the total number of references at this site is 388). A high degree of postranslational modi!ca-









Figure . Localization of Matrin3  in the anterior horn of the human spinal cord ofControl, sALS and fALS 
patients. A Schematic of the anterior horn of the human spinal cord. B Immunohistochemistry images of the 
anterior horn of the human spinal cord from una"ected (control). C Immunohistochemistry images of the 
anterior horn of the human spinal cord from sALS patients. D Immunohistochemistry images of the anterior 
horn of the human spinal cord from fALS patients with three di"erent SOD1 mutations. E Immunohisto-














































































In silico analyses predict Matrin3 as a disordered protein. A Charge-hydropathy plot predicts Matrin3 as a disordered protein. The plot is produced using PONDR webserver. A linear 
boundary can mostly separate the ordered (blue) and disorder proteins (red). Matrin-3 and FUS/TLS both fall on the disordered side of the plot, while TDP-43 falls on the ordered side. 
Plotting was performed in MATLAB.  Four webservers MFDp2, PONDR-Fit, IUPred2A, and DISOPRED3 were chosen were used tp predict the disordered domains for: B TDP-43 and C 
Matrin3. A con!dence value below 0.5 indicates a residue is likely to belong to an ordered region, while a value above 0.5 indicates a residue is likely to belong to a disordered region. 
Motifs/domains are drawn and placed approximately to scale. Lower values indicate the boundaries while upper values indicate the con!dence of the assignment. Areas with motif 
or domain assignment show increased order as well as a 50 residue stretch in the N-terminal region (100-150). Plotting was performed in Graphpad Prism.
Matrin-3 post-translational modi!cations. PhosphoSitePlus data was plotted for the human Matrin-3 entry. Low- and 
high-throughput numbers were summed for each site. The magnitude of the phosphorylation at residue S188 (denoted 
with an asterisk) was halved (the total number of references at this site is 388). A high degree of postranslational modi!ca-









Figure . Localization of Matrin3  in the anterior horn of the human spinal cord ofControl, sALS and fALS 
patients. A Schematic of the anterior horn of the human spinal cord. B Immunohistochemistry images of the 
anterior horn of the human spinal cord from una"ected (control). C Immunohistochemistry images of the 
anterior horn of the human spinal cord from sALS patients. D Immunohistochemistry images of the anterior 
horn of the human spinal cord from fALS patients with three di"erent SOD1 mutations. E Immunohisto-











A Charge-hydropathy plot predicts Matrin3 to be a mostly disordered protein. The plot was 
produced using the PONDR webserver. A clear boundary mostly separates the ordered (blue) and 
disordered proteins (red). Matrin-3 and FUS/TLS both fall on the disordered side of the plot, while 
TDP-43 falls on the ordered side. Plotting was performed in MATLAB.  Four webservers MFDp2, 
PONDR-Fit, IUPred2A, and DISOPRED3 were used to predict intrinsically disordered domains 
for: B TDP-43 as an example of a well-described misfolded protein in ALS and C Matrin3. A 
confidence value below 0.5 indicates that a residue likely belongs to an ordered region, while a 
value above 0.5 indicates that a residue likely belongs to a disordered region. Motifs/domains are 




































3.3. Matrin3 yeast model 
3.3.1. WT Matrin3  
 
We aimed to establish and characterize a yeast model expressing human full-length, wild-type 
(WT) Matrin3. Therefore, I determined the toxicity and localization of human Matrin3 expressed 
in yeast.  To this end, we established a yeast model expressing full-length WT-Matrin3 by using 
both a low copy (centromeric) vector with a constitutive promotor (GPD) for low expression and 
a high copy number 2-micron plasmids with the galactose inducible promotor (GAL) for high, 
inducible expression. We also fused the human full-length WT Matrin3 to the yellow fluorescent 
protein (Matrin3-YFP) on its carboxyl terminus to determine its localization in yeast cells by 
fluorescence microscopy. These Matrin3 constructs were transformed and expressed in yeast 
(Figure 13, A). 
We performed yeast growth assay to determine the effect of Matrin3 expression on yeast cell 
growth. At low level of expression, WT Matrin3 shows a significant growth defect compared to 
the vector control. This growth defect was exacerbated with the higher expression level of the 
Matrin3 (Figure 13, B). 
We performed western blot analyses on protein lysates from yeast cells expressing the different 
levels of Matrin3. Our results show that yeast cells expressing Matrin3 at high levels show a 3-
fold increase in the Matrin3 levels compared to low expression cells (Figure 14). 
Finally, we used fluorescence microscopy to monitor yeast cells expressing Matrin3-YFP. We 



























A Diagram of Matrin3 protein. B Growth assay of yeast cells expressing WT Matrin3 under normal 
growth conditions (30°C). C Quantification of the spotting assays as in A, (n=3), **p<0.01, 

















Figure: Expressing Matrin3 ALS-associated missense variants in the 
yeast model. A Schematic representation of the ALS-associated 
Matrin3 missense variants F115C, and T622A. B Growth assay of 
yeast cells expressing each Matrin3 missense variants (S85C, F115C, 
and T622A) as well as the YFP fusion under normal growth conditions 
(30°C). C Quantification of the spotting assay in A, (n=3), 
****p<0.0001, ns: non significant, one-way ANOVA with Tukey’s 
post-hoc test. 
Figure: Matrin3 ALS associated mutantions did not change Matrin3 
protein levels in the yeast model. A Western blot of yeast protein lysates 
showing WT and Matrin3 ALS associated variants expression levels in 
yeast cells. B Quantification of the western blot in A, (n=3), ns: non-sig-






ALS associated mutants does not a!ect Matrin3 localization in the yeast 
model. Fluorescence microscopy image of A WT Matrin3 and ALS variants (B 
F115C and C T622A) illustrating the formation of nuclear and cytosolic inclu-






Figure: Matrin3 S188A and S610D mutantions significantly reduced Matrin3 growth 
defect in  the yeast model. A Schematic representation of the three Matrin3 phosphory-
lation sites mutated. B Growth assay of yeast cells expressing either WT Matrin3 or 
Matrin3 phospho-mutants  (S188A, S188D, S610A, S610D, T622A, T622D ) under 
normal growth conditions (30°C). C Quantification of the spotting assay in A, (n=3), 
***p<0.001, ****p<0.0001, one-way ANOVA with Tukey’s post-hoc test)  
Figure: S188A mutation leads to Matrin3 
degradation in the yeast model. A Western blot 
of yeast protin lysates showing Matrin3 
expression level of either WT or Matrin3 phos-
pho-mutants (S188A, S188D, S610A, S610D, 
T622A, T622D). B Quantification of the west-
ern blot in A, (n=3), **p<0.01, one-way 
ANOVA with Tukey’s post-hoc test).   
Figure High and low expression of WT Matrin3 in the yeast model. 
A Western blot of yeast protein lysates showing different WT 
Matrin3 expression levels in yeast cells. B Quantification of the 
western blot in A, (n=3),  ***p<0.001, t.test with Tukey’s post-hoc 
test.  
Figure: Expression of WT Matrin3 causes a growth defect in the yeast 
model. A A diagram of Matrin3 protein. B Growth assay of yeast cells 
expressing different WT Matrin3  levels in yeast cells under normal 
growth conditions (30°C). C Quantification of the spotting assay in A, 



























Matrin3 forms nuclear and cytosolic inclusions in the yeast model. 
Fluorescence microscopy image of WT Matrin3 A High expression B 
Low expression illustrating the formation of Matrin3 nuclear and 
cytosolic inclusions in the yeast cells. C Fluorescence microscopy 
image of WT Matrin3 at higher magni"cation
Figure: Matrin3 N. Terminal truncated fragments 
caused a significant growth defect in  the yeast 
model. A Schematic representation of the 
designed Matrin3 N. Terminal truncated 
Figure: Matrin3 N. Terminal 399 (-RRM1) aa fragment shows a 
significant increase in the steady-state protein levels compared 
to WT Matrin3. A Western blot of yeast protein lysates showing 
HA-tagged-Matrin3 N. Terminal truncated fragments in yeast 
cells.  B Quantification of the western blot in A, (n=3), ns: 
non-significant, *p<0.05, **p<0.01, ****p<0.0001 one-way 





























































































































































































N. Terminal 287 F115C
N. Terminal 399 F115C
C
ALS associated mutants does not affect Matrin3 localization 
in the yeast model. Fluorescence microscopy image of A 











































































































































































































































































































































































































































































































A Western blot prepared with protein lysates from yeast cells expressing WT Matrin3 at different 
expression levels. B Quantification of western blots as shown A, (n=3), ***p<0.001, t-test with 




















Fluorescence microscopy of human full-length WT Matrin3 fused to YFP (yellow fluorescent 
protein). A High expression B Low expression illustrating the formation of nuclear and cytosolic 






N. Terminal 399 F115C YFP 
N. Terminal 399 YFP 

















3.3.2. Yeast model expressing ALS-associated Matrin3 variants 
 
Next, we tested the effect of the ALS-associated missense mutations on Matrin3 in the yeast model. 
To this end, I genetically engineered the expression vectors for the two Matrin3 variants, F115C 
and T622A, and the corresponding carboxy-terminal YFP fusions and transformed them into yeast 
cells (Figure 16, A). For these experiments we only used the high expression systems (2-micron 
plasmid, GAL promotor). 
First, we determined if these mutations lead to a change in the growth defect observed for WT 
Matrin3 expression in yeast. We performed growth assays with the two Matrin3 variants, which 
showed no significant difference when compared to WT Matrin3 (Figure 16).  Then, we also   
performed a western blot analyses on yeast protein lysates to determine whether there are any 
differences in the protein levels between WT Matrin3 and the two variants. The results of the 
western blot demonstrate that there was no significant difference in the steady-state protein levels 
between the two ALS-associated variants and WT Matrin3 (Figure 17). Finally, fluorescent 
microscopy further confirmed no changes in the localization between the variants and WT Matrin3 

























A Schematic representation of the ALS-associated Matrin3 missense variants F115C and T622A. 
B Growth assay of yeast cells expressing each Matrin3 missense variants (F115C, and T622A) 
and their YFP fusion under normal growth conditions (30°C). C Quantification of spotting assays 












Figure: Expressing Matrin3 ALS-associated missense variants in the 
yeast model. A Schematic representation of the ALS-associated 
Matrin3 missense variants F115C, and T622A. B Growth assay of 
yeast cells expressing each Matrin3 missense variants (S85C, F115C, 
and T622A) as well as the YFP fusion under normal growth conditions 
(30°C). C Quantification of the spotting assay in A, (n=3), 
****p<0.0001, ns: non significant, one-way ANOVA with Tukey’s 
post-hoc test. 
Figure: Matrin3 ALS associated mutantions did not change Matrin3 
protein levels in the yeast model. A Western blot of yeast protein lysates 
showing WT and Matrin3 ALS associated variants expression levels in 
yeast cells. B Quantification of the western blot in A, (n=3), ns: non-sig-






ALS associated mutants does not a!ect Matrin3 localization in the yeast 
model. Fluorescence microscopy image of A WT Matrin3 and ALS variants (B 
F115C and C T622A) illustrating the formation of nuclear and cytosolic inclu-






Figure: Matrin3 S188A and S610D mutantions significantly reduced Matrin3 growth 
defect in  the yeast model. A Schematic representation of the three Matrin3 phosphory-
lation sites mutated. B Growth assay of yeast cells expressing either WT Matrin3 or 
Matrin3 phospho-mutants  (S188A, S188D, S610A, S610D, T622A, T622D ) under 
normal growth conditions (30°C). C Quantification of the spotting assay in A, (n=3), 
***p<0.001, ****p<0.0001, one-way ANOVA with Tukey’s post-hoc test)  
Figure: S188A mutation leads to Matrin3 
degradation in the yeast model. A Western blot 
of yeast protin lysates showing Matrin3 
expression level of either WT or Matrin3 phos-
pho-mutants (S188A, S188D, S610A, S610D, 
T622A, T622D). B Quantification of the west-
ern blot in A, (n=3), **p<0.01, one-way 
ANOVA with Tukey’s post-hoc test).   
Figure High and low expression of WT Matrin3 in the yeast model. 
A Western blot of yeast protein lysates showing different WT 
Matrin3 expression levels in yeast cells. B Quantification of the 
western blot in A, (n=3),  ***p<0.001, t.test with Tukey’s post-hoc 
test.  
Figure: Expression of WT Matrin3 causes a growth defect in the yeast 
model. A A diagram of Matrin3 protein. B Growth assay of yeast cells 
expressing different WT Matrin3  levels in yeast cells under normal 
growth conditions (30°C). C Quantification of the spotting assay in A, 



























Matrin3 forms nuclear and cytosolic inclusions in the yeast model. 
Fluorescence microscopy image of WT Matrin3 A High expression B 
Low expression illustrating the formation of Matrin3 nuclear and 
cytosolic inclusions in the yeast cells. C Fluorescence microscopy 
image of WT Matrin3 at higher magni"cation
Figure: Matrin3 N. Terminal truncated fragments 
caused a significant growth defect in  the yeast 
model. A Schematic representation of the 
designed Matrin3 N. Terminal truncated 
Figure: Matrin3 N. Terminal 399 (-RRM1) aa fragment shows a 
significant increase in the steady-state protein levels compared 
to WT Matrin3. A Western blot of yeast protein lysates showing 
HA-tagged-Matrin3 N. Terminal truncated fragments in yeast 
cells.  B Quantification of the western blot in A, (n=3), ns: 
non-significant, *p<0.05, **p<0.01, ****p<0.0001 one-way 





























































































































































































N. Terminal 287 F115C
N. Terminal 399 F115C
C
ALS associated mutants does not affect Matrin3 localization 
in the yeast model. Fluorescence microscopy image of A 























































































































































































































































































































































































































































































Figure: Expressing Matrin3 ALS-associated missense variants in the 
yeast model. A Schematic representation of the ALS-associated 
Matrin3 missense variants F115C, and T622A. B Growth assay of 
yeast cells expressing each M trin3 misse se variants (S85C, F115C, 
and T622A) as well as the YFP fusion under normal growth conditions 
(30°C). C Quantification of the spotting assay in A, (n=3), 
****p<0.0001, ns: non significant, one-way ANOVA with Tukey’s 
post-hoc test. 
Figure: Matrin3 ALS associated mutantions did not change Matrin3 
protein levels in the yeast model. A Western blot of yeast protein lysates 
showing WT and Matrin3 ALS associated variants expression levels in 
yeast cells. B Quantification of the western blot in A, (n=3), ns: non-sig-






ALS associated mutants does not a!ect Matrin3 localization in the yeast 
model. Fluorescence microscopy image of A WT Matrin3 and ALS variants (B 
F115C and C T622A) illustrating the formation of nuclear and cytosolic inclu-






Figure: Matrin3 S188A and S610D mutantions significantly reduced Matrin3 growth 
defect in  the yeast model. A Schematic representation of the three Matrin3 phosphory-
lation sites mutated. B Growth assay of yeast cells expressing either WT Matrin3 or 
Matrin3 phospho-mutants  (S188A, S188D, S610A, S610D, T622A, T622D ) under 
normal growth conditions (30°C). C Quantification of the spotting assay in A, (n=3), 
***p<0.001, ****p<0.0001, one-way ANOVA with Tukey’s post-hoc test)  
Figure: S188A mutation leads to Matrin3 
degradation in the yeast model. A Western blot 
of yeast protin lysates showing Matrin3 
expression level of either WT or Matrin3 phos-
pho-mutants (S188A, S188D, S610A, S610D, 
T622A, T622D). B Quantification of the west-
ern blot in A, (n=3), **p<0.01, one-way 
ANOVA with Tukey’s post-hoc test).   
Figure High and low expression of WT Matrin3 in the yeast model. 
A Western blot of yeast protein lysates showing different WT 
Matrin3 expression levels in yeast cells. B Quantification of the 
western blot in A, (n=3),  ***p<0.001, t.test with Tukey’s post-hoc 
test.  
Figure: Expression of WT Matrin3 causes a growth defect in the yeast 
model. A A diagram of Matrin3 protein. B Growth assay of yeast cells 
expressing different WT Matrin3  levels in yeast cells under normal 
growth conditions (30°C). C Quantification of the spotting assay in A, 



























Matrin3 forms nuclear and cytosolic inclusions in the yeast model. 
Fluorescence microscopy image of WT Matrin3 A High expression B 
Low expression illustrating the formation of Matrin3 nuclear and 
cytosolic inclusions in the yeast cells. C Fluorescence microscopy 
image of WT Matrin3 at higher magni"cation
Figure: Matrin3 N. Terminal truncated fragm nts 
caused a significant growth defect in  the yeast 
model. A Schematic representation of the 
designed Matrin3 N. Terminal truncated 
Figure: Matrin3 N. Terminal 399 (-RRM1) aa fragment shows a 
significant increase in the steady-state protein levels compared 
to WT Matrin3. A Western blot of yeast protein lysates showing 
HA-tagged-Matrin3 N. Terminal truncated fragments in yeast 
cells.  B Quantification of the western blot in A, (n=3), ns: 
non-significant, *p<0.05, **p<0.01, ****p<0.0001 one-way 





























































































































































































N. Terminal 287 F115C
N. Terminal 399 F115C
C
ALS associated mutants does not affect Matrin3 localization 
in the yeast model. Fluorescence microscopy image of A 













































































































































































































































































































































































































































































































A Western blot of yeast protein lysates showing WT and Matrin3 ALS associated variants 
expression levels in yeast. B Quantification of the western blots as shown in A (n=3), ns: non-






















































































Fluorescence microscopy image of A WT Matrin3 and ALS variants, B F115C, and C T622A 
illustrating the formation of nuclear and cytosolic inclusions in yeast cells expressing WT Matrin3 






N. Terminal 399 F115C YFP 
N. Terminal 399 YFP 


















3.4. Matrin3 phospho-variants 
3.4.1. Matrin3 phospho-variants in yeast 
 
After establishing the Matrin3 yeast model, I investigated the effect of phosphorylation on Matrin3 
toxicity and localization. To this end, I introduced amino acid substitutions at three 
phosphorylation sites in Matrin3; Serine 188 (S188), Serine 610 (S610) and threonine 622 
(T622), using site directed mutagenesis (Figure 19, A). These three phosphorylation sites were 
chosen because S188A had the highest number of citations according to my in-silico analysis on 
Matrin3 phosphorylation, and the other two sites are two mutation sites found in fALS patients. I 
engineered two substitutions for each phospho-site, once with alanine, which prevents this site 
from being phosphorylated, and once with aspartic acid, which can mimic a phosphorylation site 
due to it carrying a negative charge (Figure 19, A) and transformed them into yeast cells. First, I 
determined if these mutations lead to a change in the growth defect caused by WT Matrin3 in 
yeast. We performed growth assays with the two Matrin3 phospho-variants, which showed that 
the growth defect caused by the S188A and S610D variants was significantly reduced compared 
to WT Matrin3 (Figure 19, B).  
I performed western blot analyses on yeast protein lysates to determine whether there are any 
differences in the steady-state protein levels between WT Matrin3 and the phospho-variants. The 
results of the western blots demonstrated that the S188A variant showed a significant decrease in 
the steady-state protein levels compared to WT Matrin3, while there was no significant difference 
between WT Matrin3 and the remaining variants (Figure 20, A).  
Finally, fluorescent microscopy demonstrated that the S610D variant showed only nuclear 
localization and reduced the formation of Matrin3 inclusions. By contrast, the remaining variants 










Figure 19: Matrin3 S188A and S610D mutations significantly reduced Matrin3-associated 





























Figure: Expressing Matrin3 ALS-associated missense variants in the 
yeast model. A Schematic representation of the ALS-associated 
Matrin3 missense variants F115C, and T622A. B Growth assay of 
yeast cells expressing each Matrin3 missense variants (S85C, F115C, 
and T622A) as well as the YFP fusion under normal growth conditions 
(30°C). C Quantification of the spotting assay in A, (n=3), 
****p<0.0001, ns: non significant, one-way ANOVA with Tukey’s 
post-hoc test. 
Figure: Matrin3 ALS associated mutantions did not change Matrin3 
protein levels in the yeast model. A Western blot of yeast protein lysates 
showing WT and Matrin3 ALS associated variants expression levels in 
yeast cells. B Quantification of the western blot in A, (n=3), ns: non-sig-







ALS associated mutants does not a!ect Matrin3 localization in the yeast 
model. Fluorescence microscopy image of A WT Matrin3 and ALS variants (B 
F115C and C T622A) illustrating the formation of nuclear and cytosolic inclu-






Figure: Matrin3 S188A and S610D mutantions significantly reduced Matrin3 growth 
defect in  the yeast model. A Schematic representation of the three Matrin3 phosphory-
lation sites mutated. B Growth assay of yeast cells expressing either WT Matrin3 or 
Matrin3 phospho-mutants  (S188A, S188D, S610A, S610D, T622A, T622D ) under 
normal growth conditions (30°C). C Quantification of the spotting assay in A, (n=3), 
***p<0.001, ****p<0.0001, one-way ANOVA with Tukey’s post-hoc test)  
Figure: S188A mutation leads to Matrin3 
degradation in the yeast model. A Western blot 
of yeast protin lysates showing Matrin3 
expression level of either WT or Matrin3 phos-
pho-mutants (S188A, S188D, S610A, S610D, 
T622A, T622D). B Quantification of the west-
ern blot in A, (n=3), **p<0.01, one-way 
ANOVA with Tukey’s post-hoc test).   
Figure High and low expression of WT Matrin3 in the yeast model. 
A Western blot of yeast protein lysates showing different WT 
Matrin3 expression levels in yeast cells. B Quantification of the 
western blot in A, (n=3),  ***p<0.001, t.test with Tukey’s post-hoc 
test.  
Figure: Expression of WT Matrin3 causes a growth defect in the yeast 
model. A A diagram of Matrin3 protein. B Growth assay of yeast cells 
expressing different WT Matrin3  levels in yeast cells under normal 
growth conditions (30°C). C Quantification of the spotting assay in A, 



























Matrin3 forms nuclear and cytosolic inclusions in the yeast model. 
Fluorescence microscopy image of WT Matrin3 A High expression B 
Low expression illustrating the formation of Matrin3 nuclear and 
cytosolic inclusions in the yeast cells. C Fluorescence microscopy 
image of WT Matrin3 at higher magni"cation
Figure: Matrin3 N. Terminal truncated fragments 
caused a significant growth defect in  the yeast 
model. A Schematic representation of the 
designed Matrin3 N. Terminal truncated 
Figure: Matrin3 N. Terminal 399 (-RRM1) aa fragment shows a 
significant increase in the steady-state protein levels compared 
to WT Matrin3. A Western blot of yeast protein lysates showing 
HA-tagged-Matrin3 N. Terminal truncated fragments in yeast 
cells.  B Quantification of the western blot in A, (n=3), ns: 
non-significant, *p<0.05, **p<0.01, ****p<0.0001 one-way 



































































































































































































N. Terminal 287 F115C
N. Terminal 399 F115C
C
ALS associated mutants does not affect Matrin3 localization 
in the yeast model. Fluorescence microscopy image of A 




















































































































































































































































































































































































































































































































A Western blot of yeast protein lysates showing Matrin3 expression level of either WT or Matrin3 
phospho-variants (S188A, S188D, S610A, S610D, T622A, T622D). B Quantification of western 
blots as in A, (n=3), **p<0.01, one-way ANOVA with Tukey’s post-hoc test).   
 
 
Figure: Expressing Matrin3 ALS-associated missense variants in the 
yeast model. A Schematic representation of the ALS-associated 
Matrin3 missense variants F115C, and T622A. B Growth assay of 
yeast cells expressing each Matrin3 missense variants (S85C, F115C, 
and T622A) as well as the YFP fusion under normal growth conditions 
(30°C). C Quantification of the spotting assay in A, (n=3), 
****p<0.0001, ns: non significant, one-way ANOVA with Tukey’s 
post-hoc test. 
Figure: Matrin3 ALS associated mutantions did not change Matrin3 
protein levels in the yeast model. A Western blot of yeast protein lysates 
showing WT and Matrin3 ALS associated variants expression levels in 
yeast cells. B Quantification of the western blot in A, (n=3), ns: non-sig-






ALS associated mutants does not a!ect Matrin3 localization in the yeast 
model. Fluorescence microscopy image of A WT Matrin3 and ALS variants (B 
F115C and C T622A) illustrating the formation of nuclear and cytosolic inclu-






Figure: Matrin3 S188A and S610D mutantions significantly reduced Matrin3 growth 
defect in  the yeast model. A Schematic representation of the three Matrin3 phosphory-
lation sites mutated. B Growth assay of yeast cells expressing either WT Matrin3 or 
Matrin3 phospho-mutants  (S188A, S188D, S610A, S610D, T622A, T622D ) under 
normal growth conditions (30°C). C Quantification of the spotting assay in A, (n=3), 
***p<0.001, ****p<0.0001, one-way ANOVA with Tukey’s post-hoc test)  
Figure: S188A mutation leads to Matrin3 
degradation in the yeast model. A Western blot 
of yeast protin lysates showing Matrin3 
expression level of either WT or Matrin3 phos-
pho-mutants (S188A, S188D, S610A, S610D, 
T622A, T622D). B Quantification of the west-
ern blot in A, (n=3), **p<0.01, one-way 
ANOVA with Tukey’s post-hoc test).   
Figure High and low expression of WT Matrin3 in the yeast model. 
A Western blot of yeast protein lysates showing different WT 
Matrin3 expression levels in yeast cells. B Quantification of the 
western blot in A, (n=3),  ***p<0.001, t.test with Tukey’s post-hoc 
test.  
Figure: Expression of WT Matrin3 causes a growth defect in the yeast 
model. A A diagram of Matrin3 protein. B Growth assay of yeast cells 
expressing different WT Matrin3  levels in yeast cells under normal 
growth conditions (30°C). C Quantification of the spotting assay in A, 



























Matrin3 forms nuclear and cytosolic inclusions in the yeast model. 
Fluorescence microscopy image of WT Matrin3 A High expression B 
Low expression illustrating the formation of Matrin3 nuclear and 
cytosolic inclusions in the yeast cells. C Fluorescence microscopy 
image of WT Matrin3 at higher magni"cation
Figure: Matrin3 N. Terminal truncated fragments 
caused a significant growth defect in  the yeast 
model. A Schematic representation of the 
designed Matrin3 N. Terminal truncated 
Figure: Matrin3 N. Terminal 399 (-RRM1) aa fragment shows a 
significant increase in the steady-state protein levels compared 
to WT Matrin3. A Western blot of yeast protein lysates showing 
HA-tagged-Matrin3 N. Terminal truncated fragments in yeast 
cells.  B Quantification of the western blot in A, (n=3), ns: 
non-significant, *p<0.05, **p<0.01, ****p<0.0001 one-way 





























































































































































































N. Terminal 287 F115C
N. Terminal 399 F115C
C
ALS associated mutants does not affect Matrin3 localization 
in the yeast model. Fluorescence microscopy image of A 























































































































































































































































































































































































































































































Figure: Expressing Matri 3 ALS-associated mi sense variants in the 
yeast model. A Schematic r prese tation of the ALS-associ ted 
Matrin3 missense variants F115C, and T622A. B Growth assay of 
yeast cells expressing each Matrin3 missense variants (S85C, F115C, 
and T622A) as well as the YFP fusion under normal growth conditions 
(30°C). C Quantification of the spotting assay in A, (n=3), 
****p<0.0001, ns: non significant, one-way ANOVA with Tukey’s 
post-hoc test. 
Figure: Matrin3 ALS associated mutantions did not change Matrin3 
protein levels in the yeast model. A Western blot of yeast protein lysates 
showing WT and Matrin3 ALS associated variants expression levels in 
yeast cells. B Quantification of the western blot in A, (n=3), ns: non-sig-






ALS associated mutants does not a!ect Matrin3 localization in the yeast 
model. Fluorescence microscopy image of A WT Matrin3 and ALS variants (B 
F115C and C T622A) illustrating the formation of nuclear and cytosolic inclu-






Figure: Matrin3 S188A and S610D mutantions sig ificantly reduced Matrin3 growth 
defect in  the yeast model. A Schematic representatio  of the three Matrin3 phosphory-
lation sites mutated. B Growth assay of yeast cells expressing either WT Matrin3 or 
Matrin3 phospho-mutants  (S188A, S188D, S610A, S610D, T622A, T622D ) under 
normal growth conditions (30°C). C Quantification of the spotting assay in A, (n=3), 
***p<0.001, ****p<0.0001, one-way ANOVA with Tukey’s post-hoc test)  
Figure: S188A mutation leads to Matrin3 
degradation in the yeast model. A Western blot 
of yeast protin lysates showing Matrin3 
expression level of either WT or Matrin3 phos-
pho-mutants (S188A, S188D, S610A, S610D, 
T622A, T622D). B Quantification of the west-
ern blot in A, (n=3), **p<0.01, one-way 
ANOVA with Tukey’s post-hoc test).   
Figure High and low expression of WT Matrin3 in the yeast model. 
A Western blot of yeast protein lysates showing different WT 
Matrin3 expression levels in yeast cells. B Quantification of the 
western blot in A, (n=3),  ***p<0.001, t.test with Tukey’s post-hoc 
test.  
Figure: Expression of  atrin3 cau es a growth defect in the yeast 
model. A A diagram of Matrin3 protein. B Growth assay of yeast cells 
expressing different WT Matrin3  levels in yeast cells under normal 
growth conditions (30°C). C Quantification of the spotting assay in A, 



























Matrin3 forms nuclear and cytosolic inclusions in the yeast model. 
Fluorescence microscopy image of WT Matrin3 A High expression B 
Low expression illustrating the formation of Matrin3 nuclear and 
cytosolic inclusions in the yeast cells. C Fluorescence microscopy 
image of WT Matrin3 at higher magni"cation
Figure: Matrin3 N. Terminal truncated fragments 
caused a significant growth defect in  the yeas  
model. A Schematic representation of the 
designed Matrin3 N. Terminal truncated 
Figure: Matrin3 N. Terminal 399 (-RRM1) aa fragment shows a 
significant increase in the steady-state protein levels compared 
to WT Matrin3. A Western blot of yeast protein lysates showing 
HA-tagged-Matrin3 N. Terminal truncated fragments in yeast 
cells.  B Quantification of the western blot in A, (n=3), ns: 
non-significant, *p<0.05, **p<0.01, ****p<0.0001 one-way 





























































































































































































N. Terminal 287 F115C
N. Terminal 399 F115C
C
ALS associated mutants does not affect Matrin3 localization 
in the yeast model. Fluorescence microscopy image of A 




























































































































































































































































































































































































































































































Figure 21: S188A mutations leads to Matrin3 and S610D mutations inhibits Matrin3 




Fluorescence microscopy image of A WT Matrin3 and B - G engineered phosphorylation variants 
(S188A, S188D, S610A, S610D, T622A, T622D) illustrating the effect of the phospho-mutations 
on Matrin3 localization in yeast cells. 
 
S188A leads to Matrin3 degradation and S610D  inhibits Matrin3 inclusion formation in the yeast model. Fluorescence microscopy image 
of A WT Matrin3and  B - G designed phosphorylation variants (S188A, S188D, S610A, S610D, T622A, T622D) illustrating the e!ect of the 
















S188A and S610D variants show reduced nuclear inclusion formation compared to WT Matrin3. Immuno"uorescence microscopy image 
of A Empty vector, B Endogenous Matrin3 C HA-tagged-WT Matrin3 and  D - I HA-tagged phosphorylation variants (S188A, S188D, 
S610A, S610D, T622A, T622D) illustrating the e!ect of the phospho-mutations on Matrin3 localization in SN56 Cells (Passage num-
ber=10). 
N. Terminal 399(-RRM1) truncated fragment leads to the forma-
tion of nuclear and cytoplasmic inclusions.  Immuno"uorescence 
microscopy image of A HA-tagged-WT Matrin3 and B 
HA-tagged-N. Terminal 399 fragment illustrating Matrin3 localiza-















N. Terminal 399 HA











3.4.2. Matrin3 phospho-variants in SN65 cells 
 
To further study Matrin3 phospho-variants, I genetically engineered Matrin3 phospho-mutants 
into mammalian cell expression vectors and transfected them into SN56 cells. SN56 were chosen 
because it is mouse cholinergic septal neuronal cell line that is frequently used to study 
neurodegeneration. First, I performed immunofluorescence microscopy on the HA-tagged Matrin3 
phospho-variants to determine the effect of the mutations on Matrin3 localization. My results 
showed that over-expression of WT-Matrin3 led to increased formation of nuclear inclusions 
compared to endogenous Matrin3 expression. Our results also showed that the S610D variant 
resulted in decreased inclusions formation while T622D variant showed increased mis-localization 
to the cytosol. (Figure 22). Second, I performed viability assays to determine the effect of the 
phospho-variants on Matrin3 toxicity. Our results showed that ectopic expression of WT-Matrin3 
resulted in a significant reduction of the viability of SN56 cells compared to empty vector-
transfected cells. Our results also showed that the three phospho-variants S610D, T622A and 




















Figure 22: Matrin3 phospho-variants localization in SN56 cells. 
 
Immunofluorescence microscopy image of SN56 cells expressing A empty vector, B endogenous 
Matrin3 C HA-tagged-WT Matrin3 and D - I HA-tagged phospho-variants (S188A, S188D, 
S610A, S610D, T622A, T622D) illustrating the effect of the phospho-variants on Matrin3 
localization in SN56 cells. 
S188A leads to Matrin3 degradation and S610D  inhibits Matrin3 inclusion formation in the yeast model. Fluorescence microscopy image 
of A WT Matrin3and  B - G designed phosphorylation variants (S188A, S188D, S610A, S610D, T622A, T622D) illustrating the e!ect of the 
















S188A and S610D variants show reduced nuclear inclusion formation compared to WT Matrin3. Immuno"uorescence microscopy image 
of A Empty vector, B Endogenous Matrin3 C HA-tagged-WT Matrin3 and  D - I HA-tagged phosphorylation variants (S188A, S188D, 
S610A, S610D, T622A, T622D) illustrating the e!ect of the phospho-mutations on Matrin3 localization in SN56 Cells (Passage num-
ber=10). 
N. Terminal 399(-RRM1) truncated fragment leads to the forma-
tion of nuclear and cytoplasmic inclusions.  Immuno"uorescence 
microscopy image of A HA-tagged-WT Matrin3 and B 
HA-tagged-N. Terminal 399 fragment illustrating Matrin3 localiza-















N. Terminal 399 HA
















Quantification of viability assay of SN56 over expressing WT Matrin3 and Matrin3 Phospho-































































3.5. Analysis of the intrinsically disordered domains of Matrin3 
3.5.1. Intrinsically disordered truncated fragments of Matrin3 in yeast 
 
To determine the contribution of the intrinsically disordered amino-terminal domain on Matrin3 
toxicity and localization, we genetically engineered expression vectors of the following Matrin3 
amino-terminal truncated fragments 100, 150, 200, 287 and 399 and transformed them into yeast. 
The numbers indicate the size of each truncated fragment (Figure 24, A). First, I conducted yeast 
growth assay to determine if expression of the truncated fragments caused growth defects similar 
to expression of WT full length Marin3 in yeast. My results show that the truncated fragments 
caused a significant growth defect compared to the negative (Empty vector) control, however the 
growth defect associated with the expression of all tested truncated fragments is significantly 
reduced compared to full-length WT Matrin3 (Figure 24, B).  
Then, I performed a western blot analyses on yeast protein lysates to determine whether there are 
any differences in the protein levels between full-length WT Matrin3 and the truncated fragments. 
The results of my western blots analyses demonstrate that the steady-state protein levels of the 100 
and 150 fragments are significantly lower than WT Matrin3. Furthermore, my results show that 
the steady-state protein level of the 399 fragment is significantly higher compared to WT Matrin3 
(Figure 25, A).  
My fluorescence microscopy of yeast cells expressing Matrin3 amino-terminal 399 fragment show 
numerous and small inclusions compared to full-length WT Matrin3. These results also show that 
introducing F115C mutation to the truncated fragment resulted in bigger and less numerous 












Figure 24: Amino-terminal truncated fragments of Matrin3 caused a significant growth 
defect in the yeast model compared to the empty vector. 
 










































N. Terminal 287 F115C
N. Terminal 399 F115C
Figure: Expressing Matrin3 ALS-associated missense variants in the 
yeast model. A Schematic representation of the ALS-associated 
Matrin3 missense variants F115C, and T622A. B Growth assay of 
yeast cells expressing each Matrin3 missense variants (S85C, F115C, 
and T622A) as well as the YFP fusion under normal growth conditions 
(30°C). C Quantification of the spotting assay in A, (n=3), 
****p<0.0001, ns: non significant, one-way ANOVA with Tukey’s 
post-hoc test. 
Figure: Matrin3 ALS associated mutantions did not change Matrin3 
protein levels in the yeast model. A Western blot of yeast protein lysates 
showing WT and Matrin3 ALS associated variants expression levels in 
yeast cells. B Quantification of the western blot in A, (n=3), ns: non-sig-






ALS associated mutants does not a!ect Matrin3 localization in the yeast 
model. Fluorescence microscopy image of A WT Matrin3 and ALS variants (B 
F115C and C T622A) illustrating the formation of nuclear and cytosolic inclu-






Figure: Matrin3 S188A and S610D mutantions significantly reduced Matrin3 growth 
defect in  the yeast model. A Schematic representation of the three Matrin3 phosphory-
lation sites mutated. B Growth assay of yeast cells expressing either WT Matrin3 or 
Matrin3 phospho-mutants  (S188A, S188D, S610A, S610D, T622A, T622D ) under 
normal growth conditions (30°C). C Quantification of the spotting assay in A, (n=3), 
***p<0.001, ****p<0.0001, one-way ANOVA with Tukey’s post-hoc test)  
Figure: S188A mutation leads to Matrin3 
degradation in the yeast model. A Western blot 
of yeast protin lysates showing Matrin3 
expression level of either WT or Matrin3 phos-
pho-mutants (S188A, S188D, S610A, S610D, 
T622A, T622D). B Quantification of the west-
ern blot in A, (n=3), **p<0.01, one-way 
ANOVA with Tukey’s post-hoc test).   
Figure High and low expression of WT Matrin3 in the yeast model. 
A Western blot of yeast protein lysates showing different WT 
Matrin3 expression levels in yeast cells. B Quantification of the 
western blot in A, (n=3),  ***p<0.001, t.test with Tukey’s post-hoc 
test.  
Figure: Expression of WT Matrin3 causes a growth defect in the yeast 
model. A A diagram of Matrin3 protein. B Growth assay of yeast cells 
expressing different WT Matrin3  levels in yeast cells under normal 
growth conditions (30°C). C Quantification of the spotting assay in A, 



























Matrin3 forms nuclear and cytosolic inclusions in the yeast model. 
Fluorescence microscopy image of WT Matrin3 A High expression B 
Low expression illustrating the formation of Matrin3 nuclear and 
cytosolic inclusions in the yeast cells. C Fluorescence microscopy 
image of WT Matrin3 at higher magni"cation
Figure: Matrin3 N. Terminal truncated fragments 
caused a significant growth defect in  the yeast 
model. A Schematic representation of the 
designed Matrin3 N. Terminal truncated 
Figure: Matrin3 N. Terminal 399 (-RRM1) aa fragment shows a 
significant increase in the steady-state protein levels compared 
to WT Matrin3. A Western blot of yeast protein lysates showing 
HA-tagged-Matrin3 N. Terminal truncated fragments in yeast 
cells.  B Quantification of the western blot in A, (n=3), ns: 
non-significant, *p<0.05, **p<0.01, ****p<0.0001 one-way 





























































































































































































N. Terminal 287 F115C
N. Terminal 399 F115C
C
ALS associated mutants does not affect Matrin3 localization 
in the yeast model. Fluorescence microscopy image of A 

































































































































































































































































































































































































































































































































































A Schematic representation of the engineered Matrin3 amino-terminal truncated fragments. B 
Growth assay of yeast cells expressing either WT Matrin3 or Matrin3 truncated fragments under 
normal growth conditions (30°C). C Quantification of spotting assays as in A, (n=3), **p<0.01, 
***p<0.001, ****p<0.0001, one-way ANOVA with Tukey’s post-hoc test). 
 
 
Figure: Expressing Matrin3 ALS-associated missense variants in the 
yeast model. A Schematic representation of the ALS-associated 
Matrin3 missense variants F115C, and T622A. B Growth assay of 
yeast cells expressing each Matrin3 missense variants (S85C, F115C, 
and T622A) as well as the YFP fusion under normal growth conditions 
(30°C). C Quantification of the spotting assay in A, (n=3), 
****p<0.0001, ns: non significant, one-way ANOVA with Tukey’s 
post-hoc test. 
Figure: Matrin3 ALS associated mutantions did not change Matrin3 
protein levels in the yeast model. A Western blot of yeast protein lysates 
showing WT and Matrin3 ALS associated variants expression levels in 
yeast cells. B Quantification of the western blot in A, (n=3), ns: non-sig-






ALS associated mutants does not a!ect Matrin3 localization in the yeast 
model. Fluorescence microscopy image of A WT Matrin3 and ALS variants (B 
F115C and C T622A) illustrating the formation of nuclear and cytosolic inclu-






Figure: Matrin3 S188A and S610D mutantions significantly reduced Matrin3 growth 
defect in  the yeast model. A Schematic representation of the three Matrin3 phosphory-
lation sites mutated. B Growth assay of yeast cells expressing either WT Matrin3 or 
Matrin3 phospho-mutants  (S188A, S188D, S610A, S610D, T622A, T622D ) under 
normal growth conditions (30°C). C Quantification of the spotting assay in A, (n=3), 
***p<0.001, ****p<0.0001, one-way ANOVA with Tukey’s post-hoc test)  
Figure: S188A mutation leads to Matrin3 
degradation in the yeast model. A Western blot 
of yeast protin lysates showing Matrin3 
expression level of either WT or Matrin3 phos-
pho-mutants (S188A, S188D, S610A, S610D, 
T622A, T622D). B Quantification of the west-
ern blot in A, (n=3), **p<0.01, one-way 
ANOVA with Tukey’s post-hoc test).   
Figure High and low expression of WT Matrin3 in the yeast model. 
A Western blot of yeast protein lysates showing different WT 
Matrin3 expression levels in yeast cells. B Quantification of the 
western blot in A, (n=3),  ***p<0.001, t.test with Tukey’s post-hoc 
test.  
Figure: Expression of WT Matrin3 causes a growth defect in the yeast 
model. A A diagram of Matrin3 protein. B Growth assay of yeast cells 
expressing different WT Matrin3  levels in yeast cells under normal 
growth conditions (30°C). C Quantification of the spotting assay in A, 



























Matrin3 forms nuclear and cytosolic inclusions in the yeast model. 
Fluorescence microscopy image of WT Matrin3 A High expression B 
Low expression illustrating the formation of Matrin3 nuclear and 
cytosolic inclusions in the yeast cells. C Fluorescence microscopy 
image of WT Matrin3 at higher magni"cation
Figure: Matrin3 N. Terminal truncated fragments 
caused a significant growth defect in  the yeast 
model. A Schematic representation of the 
designed Matrin3 N. Terminal truncated 
Figure: Matrin3 N. Terminal 399 (-RRM1) aa fragment shows a 
significant increase in the steady-state protein levels compared 
to WT Matrin3. A Western blot of yeast protein lysates showing 
HA-tagged-Matrin3 N. Terminal truncated fragments in yeast 
cells.  B Quantification of the western blot in A, (n=3), ns: 
non-significant, *p<0.05, **p<0.01, ****p<0.0001 one-way 





























































































































































































N. Terminal 287 F115C
N. Terminal 399 F115C
C
ALS associated mutants does not affect Matrin3 localization 
in the yeast model. Fluorescence microscopy image of A 





















































































































































































































































































































































































































































































































































Figure 25: Amino-terminal 399 aa fragment shows a significant increase in the steady-state 
protein levels compared to WT Matrin3. 
  
 
A Western blot of yeast protein lysates showing HA-tagged full-length WT Matrin3 and amino-
terminal truncated fragments in yeast cells. Arrow heads indicate bands that specifically detect 
Matrin3 and its fragments.  B Quantification of the western blot in A, (n=3), ns: non-significant, 
*p<0.05, **p<0.01, ****p<0.0001 one-way ANOVA with Tukey’s post-hoc test. 
Figure: Expressing Matrin3 ALS-associated missense variants in the 
yeast model. A Schematic representation of the ALS-associated 
Matrin3 missense variants F115C, and T622A. B Growth assay of 
yeast cells expressing each Matrin3 missense variants (S85C, F115C, 
and T622A) as well as the YFP fusion under normal growth conditions 
(30°C). C Quantification of the spotting assay in A, (n=3), 
****p<0.0001, ns: non significant, one-way ANOVA with Tukey’s 
post-hoc test. 
Figure: Matrin3 ALS associated mutantions did not change Matrin3 
protein levels in the yeast model. A Western blot of yeast protein lysates 
showing WT and Matrin3 ALS associated variants expression levels in 
yeast cells. B Quantification of the western blot in A, (n=3), ns: non-sig-






ALS associated mutants does not a!ect Matrin3 localization in the yeast 
model. Fluorescence microscopy image of A WT Matrin3 and ALS variants (B 
F115C and C T622A) illustrating the formation of nuclear and cytosolic inclu-






Figure: Matrin3 S188A and S610D mutantions significantly reduced Matrin3 growth 
defect in  the yeast model. A Schematic representation of the three Matrin3 phosphory-
lation sites mutated. B Growth assay of yeast cells expressing either WT Matrin3 or 
Matrin3 phospho-mutants  (S188A, S188D, S610A, S610D, T622A, T622D ) under 
normal growth conditions (30°C). C Quantification of the spotting assay in A, (n=3), 
***p<0.001, ****p<0.0001, one-way ANOVA with Tukey’s post-hoc test)  
Figure: S188A mutation leads to Matrin3 
degradation in the yeast model. A Western blot 
of yeast protin lysates showing Matrin3 
expression level of either WT or Matrin3 phos-
pho-mutants (S188A, S188D, S610A, S610D, 
T622A, T622D). B Quantification of the west-
ern blot in A, (n=3), **p<0.01, one-way 
ANOVA with Tukey’s post-hoc test).   
Figure High and low expression of WT Matrin3 in the yeast model. 
A Western blot of yeast protein lysates showing different WT 
Matrin3 expression levels in yeast cells. B Quantification of the 
western blot in A, (n=3),  ***p<0.001, t.test with Tukey’s post-hoc 
test.  
Figure: Expression of WT Matrin3 causes a growth defect in the yeast 
model. A A diagram of Matrin3 protein. B Growth assay of yeast cells 
expressing different WT Matrin3  levels in yeast cells under normal 
growth conditions (30°C). C Quantification of the spotting assay in A, 



























Matrin3 forms nuclear and cytosolic inclusions in the yeast model. 
Fluorescence microscopy image of WT Matrin3 A High expression B 
Low expression illustrating the formation of Matrin3 nuclear and 
cytosolic inclusions in the yeast cells. C Fluorescence microscopy 
image of WT Matrin3 at higher magni"cation
Figure: Matrin3 N. Terminal truncated fragments 
caused a significant growth defect in  the yeast 
model. A Schematic representation of the 
designed Matrin3 N. Terminal truncated 
Figure: Matrin3 N. Terminal 399 (-RRM1) aa fragment shows a 
significant increase in the steady-state protein levels compared 
to WT Matrin3. A Western blot of yeast protein lysates showing 
HA-tagged-Matrin3 N. Terminal truncated fragments in yeast 
cells.  B Quantification of the western blot in A, (n=3), ns: 
non-significant, *p<0.05, **p<0.01, ****p<0.0001 one-way 























































































































































































N. Terminal 287 F115C
N. Terminal 399 F115C
C
ALS associated mutants does not affect Matrin3 localization 
in the yeast model. Fluorescence microscopy image of A 






































































































































































































































































































































































































































































































































Figure: Expressing Matrin3 ALS-associated missense variants  the
yeast model. A Schematic representation of the ALS-associated 
Matrin3 missense variants F115C, and T622A. B Growth assay of 
yeast cells expressing each Matrin3 missense variants (S85C, F115C, 
and T622A) as well as the YFP fusion under normal growth conditions 
(30°C). C Quantification of the spotting assay in A, (n=3), 
****p<0.0001, ns: non significant, one-way ANOVA with Tukey’s 
post-hoc test. 
Figure: Matrin3 ALS associated mutantions did not change Matrin3 
protein levels in the yeast model. A Western blot of yeast protein lysates 
showing WT and Matrin3 ALS associated variants expression levels in 
yeast cells. B Quantification of the western blot in A, (n=3), ns: non-sig-






ALS associated mutants does not a!ect Matrin3 localization in the yeast 
model. Fluorescence microscopy image of A WT Matrin3 and ALS variants (B 
F115C and C T622A) illustrating the formation of nuclear and cytosolic inclu-






Figure: Matrin3 S188A and S610D mutantions significantly reduced Matrin3 growth 
defect in  the yeast model. A Schematic representation of the three Matrin3 phosphory-
lation sites mutated. B Growth assay of yeast cells expressing either WT Matrin3 or 
Matrin3 phospho-mutants  (S188A, S188D, S610A, S610D, T622A, T622D ) under 
normal growth condi ions (30°C). C Quantification of the spotting assay in A, (n=3), 
***p<0.001, ****p<0.0001, one-way ANOVA with Tukey’s post-hoc test)  
Figure: S188A mutation leads to Matrin3 
degradation in the yeast model. A Western blot 
of yeast protin lysates showing Matrin3 
expression level of either WT or Matrin3 phos-
pho-mutants (S188A, S188D, S610A, S610D, 
T622A, T622D). B Quantification of the west-
ern blot in A, (n=3), **p<0.01, one-way 
ANOVA with Tukey’s post-hoc test).   
Figure High and low expression of WT Matrin3 in the yeast model. 
A Western blot of yeast protein lysates showing different WT 
Matrin3 expression levels in yeast cells. B Quantification of the 
western blot in A, (n=3),  ***p<0.001, t.test with Tukey’s post-hoc 
test.  
Figure: Expression of WT Matrin3 causes a growth defect in the yeast 
model. A A diagram of Matrin3 protein. B Growth assay of yeast cells 
expressing different WT Matrin3  levels in yeast cells under normal 
growth conditions (30°C). C Quantification of the spotting assay in A, 



























Matrin3 forms nuclear and cytosolic inclusions in the yeast model. 
Fluorescence microscopy image of WT Matrin3 A High expression B 
Low expression illustrating the formation of Matrin3 nuclear and 
cytosolic inclusions in the yeast cells. C Fluorescence microscopy 
image of WT Matrin3 at higher magni"cation
Figure: Matrin3 N. Terminal truncated fragments 
caused a significant growth defect in  the yeast 
model. A Schematic representation of the 
designed Matrin3 N. Terminal truncated 
Figure: Matrin3 N. Terminal 399 (-RRM1) aa fragment shows a 
significant increase in the steady-state protein levels compared 
to WT Matrin3. A Western blot of yeast protein lysates showing 
HA-tagged-Matrin3 N. Terminal truncated fragments in yeast 
cells.  B Quantification of the western blot in A, (n=3), ns: 
non-significant, *p<0.05, **p<0.01, ****p<0.0001 one-way 










































































































































































N. Terminal 287 F115C
N. Terminal 399 F115C
C
ALS associated mutants does n t affect Matrin3 localization 
in the yeast model. Fluorescence microscopy image of A 




























































































































































































































































































































































































































































































































Fluorescence microscopy image yeast cells expressing A WT-Matrin3 and B Matrin3 amino-
terminal 399 Fragment C Matrin3 F115C amino-terminal 399 fragment illustrating the 
localization of WT and Matrin3 F115C amino-terminal 399 truncated fragment in yeast. 
 
N. Terminal 399 F115C YFP 
N. Terminal 399 YFP 
















3.5.2. Intrinsically disordered truncated fragments of Matrin3 expressed in SN56 cells 
 
To further confirm our yeast results, I genetically engineered Matrin3 amino-terminal truncated 
fragment 399 into mammalian cell expression vectors and transfected them into SN56 cells. These 
constructs also contain carboxy-terminal HA epitope-tag fusion for detection by western blotting.  
First, I performed immunofluorescence microscopy on the HA-tagged Matrin3 399 fragment to 
determine its localization compared to WT Matrin3. My results show that over-expression of the 
399 fragment led to the formation of both nuclear and cytosolic inclusions (Figure 27).  
Second, I performed viability assays   to determine the effect of the amino-terminal truncated 
fragment on cellular viability. My results show that the expression of the 399 fragment results in 
a significant reduction in the viability of the SN56 cells compared to empty vector controls. This 
decrease in cell viability was not significantly different from cells expressing full-length WT 





















Figure 27: amino-terminal 399 truncated fragment leads to the formation of nuclear and 





Immunofluorescence microscopy image of A HA-tagged full-length WT Matrin3 and B HA-











Figure 28: Overexpression of the amino-terminal 399 truncated fragment significantly 




Viability assay quantification of SN56 over expressing full-length WT Matrin3 and Matrin3 



























































4.1. Aberrant Matrin3 localization in motor neurons of the anterior horn in the spinal 
cords of ALS patients 
In this study, I investigated Matrin3 localization in motor neurons in the anterior horn of the spinal 
cord in unaffected controls, and patients with sALS, and fALS carrying mutations in either 
C9orf72 or SOD. I found that Matrin3 shows granular nuclear staining, which can indicate binding 
to the chromatin or specific RNA molecules, in unaffected control without any cytosolic staining 
(Figure 9, B) as reported before.17,44 In ALS patients, Matrin3 shows changes in its localization 
compared to unaffected controls. There are, however, variation of this aberrant Matrin3 
localization depending on the individual patient and the type of ALS. 
In sALS, we observed four major discernable patterns of Matrin3 mis-localization: 1) intense 
nuclear staining without cytosolic staining; 2) intense nuclear staining with weak cytosolic 
staining; 3) complete mis-localization of Matrin3 from the nucleus showing diffuse cytosolic 
staining; and 4) Matrin3 cytosolic inclusions (Figure 9, C). In fALS, Matrin3 mis-localization 
varies according to the gene carrying the mutations, and different mutations within the same gene. 
Patients with C9orf72 mutations showed a very intense nuclear staining with very rare cytosolic 
mis-localization (Figure 9, E). In SOD1 patients, A4T and I113T mutations did not affect Matrin3 
localization compared to neurologically unaffected controls. Yet, ALS patient carrying the D76Y 
SOD1 mutation showed increased Matrin3 nuclear localization with intense diffuse cytosolic 
staining (Figure 9, D). 
Our IHC results show that Matrin3 mis-localization in patients with different types of ALS varies 
from patient to patient. Our results on Matrin3 confirmed previous studies showing Matrin3 
pathology in patients with sALS and fALS carrying mutations in C9orf72.44 Yet, of note, we 
detected aberrant Matrin3 localization in the majority of the explored ALS specimen expect for 
the SOD1 mutants A4T and I113T. This indicates that Matrin3 displays a pathological localization 
pattern in sALS and at least in some cases of fALS. While it remains unknown whether this 
aberrant Matrin3 localization indeed contributes to ALS pathogenesis, my pathological results 
suggest that Matrin3 indeed has the capacity to mis-localize and form inclusion as it has been 
observed for other ALS-associated proteins, such as TDP-43.27 My results from patients with 
SOD1 mutations could furthermore indicate that Matrin3 mis-localization does not occur in all 




mutation leads to SOD1 dysfunction and the development of severe oxidative stress inside the cell, 
which leads to Matrin3 mis-localization and inclusion formation. Our results on Matrin3 pathology 
in patients carrying mutations in SOD1 is novel and even studies focused on other RNA binding 
proteins, such as TDP-43 and FUS, did not show any proteinopathy in SOD1 patients and SOD1 
inclusions formation is highly controversial in sALS.105,106 In any case, my results indicate a 
possible specific link between SOD1 and Matrin3 that is distinct from other ALS-associated RNA 
binding proteins. 
There are some limitations to our experiment that need to be considered. First, the limited number 
of specimens, especially in the fALS cases with SOD1 mutations. We need to increase the number 
of SOD1 mutations in our study and include more patients for each mutation to get statistically 
significant results. Experiments should also be done to determine the effect of those mutations on 
the structure and functions of SOD1 and their effect on Matrin3 pathology. 
Second, we only used one anti-Matrin3 antibody (Sigma Anti-MATR3 antibody). Studies have 
shown that not all antibodies can detect Matrin3 inclusion. This was indicated in a previous study 
in which 4 different Matrin3 antibodies were used ALS patient slides, and only one anti-Matrin3 
antibody (Bethyl laboratories Anti-MATR3 antibody) detected Matrin3 inclusions. The Bethyl 
antibody in future studies since it is more sensitive to Matrin3 inclusions. 
Finally, we did not know the genetic makeup of the spinal cord sporadic ALS (sALS) patient 
samples were utilized in this study. We don’t know whether they have mutations in any of the ALS 
causing genes. We also were not able to obtain tissue sample from fALS patients with mutations 
in Matrin3 to use as a positive control in our study as done before.44 Finally, we determined the 
motor neuron cell population based on their size and morphology. To be more accurate, further 
studies should be performed by co-staining the protein of interest with specific motor neuron 
markers such as Motor Neuron and Pancreas Homeobox Protein 1(MNX1), a nuclear protein that 
has been used a reliable marker for motor neurons in previous studies. 
Nevertheless, our results showed that Matrin3 shows mis-localization in patients with different 
types of ALS. Future work includes increasing the number of unaffected controls, sALS and fALS 
carrying mutations in different genes (SOD1, TDP-43, FUS and C9orf72) cases to generate more 
representative results. Future work should also include tissue samples with other 
neurodegenerative disorders, such as Parkinson’s and Alzheimer’s disease, to determine whether 




ALS. Also, different anti-Matrin3 antibodies should be used on tissue sample to make sure that 
protein inclusions can be detected with different reagents and by recognitions of different regions 
(antigens) within Matrin3. Using conformation specific antibodies, which can recognize specific 
three-dimensional antigenic conformation can give more insight on Matrin3 changes occurring in 
ALS. Finally, subcellular fractionation should be performed to separate nuclear and cytosolic 
Matrin3. This assessment combined with the use of different detergents and protein lysis methods 
will further elucidate the biochemical nature of Matrin3 inclusions.  
 
 
4.2. Matrin3 yeast model 
Several yeast models have been established to study protein misfolding in neurodegenerative 
disorders, such as TDP-43 yeast model in ALS. TDP-43 expression leads to a growth defect and 
the formation of cytosolic soluble aggregates when expressed in yeast cells. Finally, TDP-43 
growth defects depend on the level of protein expression, making it an excellent candidate for 
high-throughput screens to identify genetic interactions that can modulate its toxicity.97 We 
established a yeast model for Matrin3 to investigate the mechanisms underlying Matrin3 
misfolding and toxicity. Similar to TDP-43, our yeast results show that Matrin3 expression in yeast 
leads to a growth defect in a dose dependent manner i.e., the higher level of Matrin3 expression, 
the more prominent the growth defect (Figure 13, B and C). As in human neurons, our results show 
that Matrin3 overexpression led to the formation of both nuclear and cytosolic inclusions in yeast 














4.3. ALS-Associated Matrin3 Variants  
We transformed the most frequently studied ALS-associated Matrin3 variants, F115C and T622A, 
into yeast. Expression of these Matrin3 ALS variants, similar to full length WT Matrin3, causes a 
significant growth defect in yeast cells (Figure 16, B and C). Our western blot and fluorescence 
microscopy do not show any changes in the steady state protein levels of the variants, or their 
localization compared to WT Matrin3 (Figure 17 and 18). This indicated that the two ALS-
associated variants might not drastically change Matrin3 misfolding in the yeast model. Our results 
recapitulate finding from previous studies conducted on Matrin3 in mammalian cells showing that 
the ALS associated variants did not show different localization patterns compared to WT Matrin3.  
Yeast models are a powerful genetic tool to study basic cellular processes, protein quality control 
and the mechanisms of protein folding and misfolding. Several yeast models have been established 
to study protein misfolding in neurodegenerative disorders, such as TDP-43 yeast model in ALS.107 
The conservation of key cellular pathways between yeast and humans, such as the cellular protein 
quality control, makes experiments in yeast directly relevant to human and can be used to decipher 
the mechanisms of the protein misfolding in neurodegenerative diseases.93 However, similar to 
any other model system, yeast has limitations that need to be carefully considered. Yeast is a 
single-celled organism that does not have differentiated cell types such as the highly differentiated 
motor neurons that are affected in ALS. Furthermore, yeast does not have an ortholog for Matrin3, 
which also means that naturally occurring protein interactions with Matrin3 do not exist in yeast 
cells. This poses a limitation since the yeast protein quality control system and molecular 
chaperones are not normally involved in the processing of the Matrin3 protein. One way to address 
this limitation was discussed before in the literature, which is to engineer yeast to possess entirely 
human chaperone pathways.102 This can help producing results that are more relevant to 
mammalian cells. Finally, many proteins that interact with Matrin3 and help carry its functions 
and possibly also maintain its proper, non-toxic conformation do not have orthologs in yeast.  This 
explains why we cannot perform experiments exploring Matrin3 function in the yeast model and 
might induce over Matrin3 misfolding. Yet the yeast model, like the aforementioned models, 





4.4. Matrin3 phosphorylation 
Matrin3 is a phosphoprotein with several serine/threonine and tyrosine phosphorylation sites. 
Here, I used Phosphositeplus to determine the phosphorylation sites in Matrin3. I found 34 serine, 
4 threonine and 3 tyrosine residues in Matrin3 that are phosphorylated (Figure 11). Some results 
from our in-silico analysis are obtained from phosphorylation prediction webservers and mass 
spectrometry on Matrin3 isolated from cancer cells. These webservers depend on certain 
algorithms or machine learning, which is prone to over-optimization when developed on small 
data sets. This poses a limitation since some of it can reduce the accuracy of the predicted results, 
which have to be confirmed by individual experiments in future studies. In any case, 
Phosphositeplus provides the number of times each site was mentioned in the literature and the 
serine 188 (S188) site has the greatest number of citations, which indicates that this 
phosphorylation occurs frequently under many different experimental conditions and in different 
systems. Our analysis also indicated that two additional sites, serine 610 (S610) and threonine 
622 (T622), are frequently found to be phosphorylated (Figure 11). I therefore focused on these 
three sites for my project. This focus was based on experimental feasibility. It is possible that there 
are phosphorylation events than the ones assessed here, and that other posttranslational 
modifications, such as ubiquitination, acetylation, and Sumoylation, can also alter Matrin3 
misfolding and toxicity as show for other misfolded proteins before.108,109 These will need to be 
explored in future studies.  
Our results show that the S188A mutant variant is expressed at very low steady-state levels 
compared to wild-type Matrin3. This can be due to either that the mRNA is not expressed, or the 
mutant proteins undergo rapid proteasomal degradation or degradation by autophagy. By contrast, 
the S188D variant did not have any effect on the growth defect caused by Matrin3 in the yeast 
model. This can indicate that the negative charge carried by the by the aspartic acid, and us also 
by a phosphate group, might have a significant role in the folding process of Matrin3 (Figure 19 
and 20). Furthermore, our results S610D mutations reduced the growth defect caused by Matrin3, 
the mutations did not change the steady state levels (Figure 19 and 20) and fluorescence 
microscopy results show that the S610D mutation changed Matrin3 localization pattern in the yeast 
model (Figure 21). The S610D variant showed only nuclear localization without forming any 




by Matrin3 and inclusion formation. The drastic changes caused by the mutation on Matrin3 
toxicity and localization indicate that the S610 phosphorylation site is significant for the proper 
folding and stability of Matrin3. 
We then confirmed our yeast results in SN56 cells. Immunofluorescence microscopy showed that 
over expression of full-length WT Matrin3 led to nuclear inclusion formation (Figure 22 and 24).  
Our results showed that S610D variant showed decreased inclusion formation, which is similar to 
our yeast results further confirming that the phosphate group is required for properMatrin3 folding. 
We also noticed that the T622D variant showed increased mis-localization to the cytosol. I did not 
notice the same results with the T622A variant indicating a possible role for the phosphorylation 
of this site in Matrin3 folding (Figure 22). To better understand the effects of the mutations on 
Matrin3 folding, biochemical approaches, such as vibrational circular dichroism, dynamic light 
scattering, and analytical ultracentrifugation should be used on purified WT and Matrin3 variants 
in biophysical experiments.  
There is evidence that phosphorylation plays a major role in the pathogenesis of other RNA 
binding proteins in ALS such as TDP-43 and FUS.110,111 Studies suggest that phosphorylation of 
the PrLD of FUS disrupts its ability to phase separate, aggregate and significantly reduces its 
toxicity.111 Studies have also shown that, in ALS, the PrLD of TDP-43 is heavily phosphorylated 
and disrupting TDP-43 at specific sites was neuroprotective.112 Taken together, the role of protein 
phosphorylation in ALS pathogenesis is still controversial and further studies are needed to further 
confirm the contribution of protein phosphorylation in ALS. 
Although further studies are required to elucidate the exact role of phosphorylation on Matrin3 
pathogenesis, our results still suggest a significant role of protein phosphorylation on Matrin3 
misfolding and pathogenesis.  
   
Even though many human genes have orthologs in yeast, there are many human genes that do not 
have yeast orthologs. This is particularly relevant to my study since there are differences between 
the human and yeast kinases. This also poses a limitation on the yeast model since Matrin3 is not 
an endogenous yeast protein and yeast kinases might not interact with it. Thus, it remains uncertain 
whether Matrin3 is phosphorylated in yeast or not, and if it is, the phosphorylation pattern might 




Matrin3 antibodies and directed mass spec experiments using our yeast model and comparing those 
results to mammalian systems, will address these open questions. 
Finally, to study the effect of phosphorylation on Matrin3 misfolding, we introduced amino acid 
substitutions. In addition to changing the phosphorylation of Matrin3, these amino acid 
substitutions change the size of side chain of the amino acid at this particular site; for example, 
replacing the serine with alanine removes the hydroxyl group in the side chain and using the 
aspartic acid can only mimic a phosphate group regarding its negative charge, but it cannot be 
considered a genuine phosphorylated site due to the absence of the phosphate group with its large 
hydration size and charge compare the carboxyl group of aspartic acid. Future in vitro studies using 
purified phosphorylated Matrin3 or Matrin3 fragments will allow overcoming these limitations. 
Nevertheless, the amino acid substitutions we used here have given profound insights into how 
phosphorylation can alter the three-dimensional conformation and function of many different 
proteins and might thus also be informative for Matrin3.  
We replicate our finding in yeast in SN56 mammalian cell line. Mammalian neuronal cells lines 
generally represent great models to study human diseases and they helped advance our 
understanding of protein misfolding and protein quality control in neurodegenerative diseases. 
SN56 in particular is a very well-established model system to study ALS since they are cholinergic 
septal neurons which makes it very close to motor neurons affected in ALS.103 However, SN56 
cells are still different from human motor neurons since they are derived from mice. SN56 cells 
are neuroblastoma cells, so they have to be regarded as cancer cells, which differ profoundly from 
permanently differentiated, non-diving motor neurons that are affected by ALS. Unlike motor 
neurons which have a finite life span, immortalized cell lines can divide indefinitely, and 
sometimes express unique gene patterns not found in any normal cell types in the CNS. To 
overcome this limitation, future studies should be conducted on primary neurons, or induced 
pluripotent stem cells (iPS cells) derived from ALS patients. 
Importantly, to confirm whether there are indeed changes in Matrin3 phosphorylation in ALS, 
mass spectrometry should be conducted on misfolded Matrin3 isolated from spinal cord samples 
of ALS patients and compared to unaffected controls, e.g., by immunoprecipitation. In addition, 
in vitro experiments should be conducted purified WT and Matrin3 phospho-variants to understand 




4.5. The intrinsically disordered domains of Matrin3 
 
Matrin3 is mostly an intrinsically disordered protein, and it can undergo LLPS under certain 
conditions as shown by my computational analyses and one published study.100 We used PONDR 
webserver to generate a charge hydropathy plot, which can predict whether the protein is ordered 
or not based on the amino acid sequence and the total charge of the protein (Figure 12, A). 
Furthermore, we used four different webservers to determine which regions in Matrin3 are 
disordered. Our analysis indicate that Matrin3 is almost completely disordered except for the well 
identified RRM and ZnF domains (Figure 12, C). 
Our In-silico analysis results were solely obtained from algorithm-based predictions and are not 
experimentally confirmed. In-vitro analyses, such as circular dichroism and nuclear magnetic 
resonance, should be performed on purified Matrin3 or Matrin3 fragments to demonstrate it 
intrinsically disordered character. Future in vitro experiment will also allow assessing whether the 
amino-terminal Matrin3 domain undergoes LLPS. 
  
We decided to focus on the amino-terminal intrinsically disordered regions since it is the largest 
continuous disordered region of Matrin3, contains the majority of the ALS-causing variants, and 
previous studies indicated that it plays a role in liquid-liquid phase separation.100 Our results show 
that all the amino-terminal truncated fragments used in my study (100, 150, 200, 287 and 399) 
caused a significant growth defect in yeast, however, the growth defect was not as strong as the 
one caused by full length WT Matrin3 (Figure 24, A and B).  
Our western blot results show that the steady state protein levels of the 100 and 150 amino acid 
truncated fragments were significantly lower that full length WT-Matrin3 (Figure 25). We 
speculate this is due to a decrease in the stability of these fragments or an increase in their 
degradation. Furthermore, our results show significant increase in the 399 fragment protein levels 
compared to full-length WT-Matrin3, which indicates increased stability of the fragment, possibly 
because of its resistance to degradation. Our fluorescence microscopy of yeast cells expressing 
Matrin3 amino-terminal 399 fragment show numerous and small inclusions compared to full-
length WT-Matrin3, which mostly formed one big inclusion inside the cell.  Based on these results 
we speculate that the amino-terminal 399 fragment undergoes LLPS, which can go awry under 




observed that introducing the ALS-associated F115C amino acid substitution to the truncated 
fragment resulted in drastic changes in protein localization, which indicates that the ALS-
associated mutation can affect the LLPS separation of the protein leading its misfolding (Figure 
26). 
Finally, we confirmed our yeast results in SN56 cells. Immunofluorescence microscopy showed 
to the formation of nuclear and rare cytosolic inclusions in transfected cells. These inclusions were 
smaller and more numerous Full-length WT-Matrin3 (Figure 27). There results were, to some 
extent, similar to our yeast results. Finally, the viability assay results showed that transfection with 
the amino-terminal 399 fragment resulted in a significant decrease in SN56 cell viability (Figure 
28). 
Previous studies on TDP-43 have shown that expressing only the carboxy-terminal PrLD did not 
lead to any growth defect, however expressing the PrLD fused to the RRM resulted in a significant 
growth defect. Yeast fluorescence microscopy of the GFP tagged PrLD of TDP-43 showed diffuse 
signaling with very rare cytosolic inclusions, but the PrLD-RRM truncation resulted in numerous 
cytosolic inclusions in the yeast model.107 These results indicate a significant role of the RNA 
binding in TDP-43 toxicity and inclusion formation. 
Our results with Matrin3 differ TDP-43. Since all the fragments lack any RNA binding motifs, our 
results provide evidence that, unlike other RNA binding proteins, such as TDP-43, the RNA 
binding ability in Matrin3 is not required to produce a toxic effect, at least in yeast models. We 
speculate that the amino-terminal domain undergoes phase separation into liquid droplets where it 














4.6. Overall conclusions and significance  
Our results confirms that Matrin3 misfolds in sALS and C9orf72 patients. This thesis thus provides 
the first evidence of Matrin3 mis-localization in patients with SOD1 mutations. We also 
established a Matrin3 yeast model to investigate the mechanisms of matrin3 misfolding. our results 
signify that protein phosphorylation regulates Matrin3 folding and changes in the phosphorylation 
can lead to protein misfolding and inclusion formation. Our results also show that amino-terminal 
disordered regions lead to inclusion formation and toxicity on its own without binding to RNA. 
This is a novel finding that can help us understand how intrinsically disordered regions drive 
protein misfolding in different neurodegenerative disorders. We propose that the protein 
phosphorylation and the amino-terminal intrinsically disordered region plays a major role 
in Matrin3 toxicity and misfolding in ALS. Finally, our study highlights the contribution of 
protein phosphorylation and intrinsically disordered regions on protein toxicity and misfolding in 
neurodegenerative disorders. Understanding the role of these two concepts in protein misfolding 
is an essential step to be able to develop more effective therapeutic approaches for different 



















Figure 29: Proposed mechanism of Matrin3 misfolding in ALS. 
 
 

























































































































































































A Under normal conditions, Matrin3 is located inside the nucleus. B ALS-associated mutations in 
the regions encoding the disordered regions of Matrin3 leads to protein misfolding, mis-
localization and the formation of nuclear and cytosolic inclusions. C In ALS, changes in Matrin3 
phosphorylation pattern may lead to protein misfolding, mis-localization and the formation of 
nuclear and cytosolic inclusions. We propose that the ALS associated mutations and changes in 
protein phosphorylation led to protein misfolding by causing defects in the liquid-liquid phase 
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Figure 30: Localization of Matrin3 in the anterior horn of the human spinal cord of 
unaffected controls, sALS and fALS patients. 
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A Immunohistochemistry images of the anterior horn of the human spinal cord from unaffected 
individuals (control). B Immunohistochemistry images of the anterior horn of the human spinal 
cord from sALS patients C Immunohistochemistry images of the anterior horn of the human spinal 






Figure 31: Yeast growth assay non-induced controls 
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Growth assay of yeast cells transformed with A Full length WT Matrin3 B Full length WT Matrin3 
and ALS associated variants C Full length WT Matrin3 and Matrin3 phospho-variants D Full 
length WT Matrin3 and Matrin3 amino-terminal truncated fragments under normal growth 



































A Western blot prepared with protein lysates from yeast cells expressing WT Matrin3 at different 
expression levels B Western blot showing the protein expression levels of PGK-1 control in 





































A Western blot prepared with protein lysates from yeast cells expressing WT Matrin3 and 
Matrin3 phospho-variants B Western blot showing the protein expression levels of PGK-1 






























Western blot showing the protein expression levels of PGK-1 control in yeast cells expressing 
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